Pharmacist-Initiated Addiction Support Network in Underserved Communities. Vision for Poland

Executive Summary

This policy paper presents a comprehensive vision for establishing a Pharmacist-Initiated Addiction Support Network in Poland to address significant gaps in substance use disorder (SUD) treatment access. Poland currently faces substantial challenges with approximately 700,000-800,000 individuals dependent on alcohol, 1.5-2 million consuming alcohol at harmful levels, and 100,000-120,000 high-risk drug users. Despite this clear need, only 15-30% of individuals with SUDs receive specialized treatment, highlighting a critical "treatment gap" particularly pronounced in rural and economically disadvantaged regions.

Poland's extensive network of over 13,000 community pharmacies represents an underutilized resource for expanding addiction services. Recent health system reforms, including the "Pharmacy for the Patient" initiative, have begun expanding pharmacists' clinical responsibilities, creating a foundation for further innovation. International models from Scotland, Canada, and Australia demonstrate pharmacists' successful integration into addiction care networks through harm reduction services, medication management, and treatment support.

The proposed model for Poland consists of four tiers of service:

1. Universal Prevention and Screening: Implementing validated screening tools, medication reviews, educational materials, and safe medication disposal
2. Harm Reduction Services: Providing needle exchange programs, naloxone distribution, fentanyl test strips, and confidential health monitoring
3. Treatment Support: Offering supervised consumption for opioid substitution therapy, medication adherence support, collaborative care with prescribers, and telehealth access
4. Recovery Support: Conducting recovery check-ins, connecting to peer support, monitoring medications, and providing family resources

Implementation would follow a phased approach: (1) a pilot phase with 50 pharmacies across five voivodeships, (2) a comprehensive evaluation phase, (3) expansion to 500 pharmacies nationwide, and (4) full implementation with necessary regulatory changes and sustainable funding models.

Success requires addressing several key challenges:

• Regulatory reforms to expand pharmacists' scope of practice
• Sustainable financing through the National Health Fund
• Comprehensive professional development for pharmacists
• Multi-stakeholder collaboration between government entities, professional organizations, civil society partners, academic institutions, and the private sector
• Robust monitoring and evaluation framework measuring implementation fidelity, health outcomes, economic impact, and equity considerations

This model leverages Poland's existing pharmacy infrastructure to significantly improve addiction care access, particularly in underserved areas. By implementing evidence-based practices adapted to Poland's unique context, this initiative has the potential to dramatically reduce the treatment gap, improve public health outcomes, and provide a more humane, effective response to substance use disorders.

Current State of Addiction Services in Poland

Poland faces substantial challenges in addressing substance use disorders (SUDs), with implications that extend across public health, economic, and social domains. Recent estimates from the Polish National Bureau for Drug Prevention (KBPN) reveal approximately 700,000 to 800,000 individuals dependent on alcohol, with an additional 1.5 to 2 million consuming alcohol at harmful levels (KBPN, 2023). The illicit drug landscape presents further concerns, with an estimated 100,000 to 120,000 high-risk drug users primarily using opioids and stimulants, while emerging new psychoactive substances (NPS) create evolving challenges for treatment providers and policymakers alike (EMCDDA, 2023a). These figures likely underrepresent the true scope of the problem due to persistent stigma and underreporting (Wojnar & Klimkiewicz, 2019). The COVID-19 pandemic has only intensified these issues, with evidence suggesting increased substance use patterns alongside diminished access to support services during lockdowns and healthcare system strain (Marsden et al., 2020; Samochowiec et al., 2021).

Despite this clear and pressing need, access to comprehensive addiction treatment remains woefully inadequate throughout Poland, with rural and economically disadvantaged regions bearing a disproportionate burden. The KBPN (2023) documents that merely 15-30% of individuals meeting clinical criteria for SUDs receive any form of specialized treatment, highlighting a substantial "treatment gap" that mirrors global challenges in addiction care delivery (World Health Organization [WHO], 2019). This gap represents not merely a statistical concern but a profound policy failure with far-reaching consequences. Similar treatment gaps persist even in countries with more robust healthcare systems; for instance, research following the implementation of the Affordable Care Act in the United States still identified significant barriers to SUD treatment, particularly among vulnerable populations (Saloner et al., 2023). The implications of this treatment gap extend beyond individual health outcomes to include increased societal costs and potential medication diversion when legitimate access pathways remain constrained (NPR, 2018; Das et al., 2021).

The current framework for addiction support in Poland relies heavily on specialized addiction centers and psychiatric facilities concentrated in urban areas, creating formidable geographical and accessibility barriers for rural populations (EMCDDA, 2023a; Gaciong & Grodzicki, 2020). This centralization mirrors challenges observed internationally, where rural populations encounter unique obstacles including transportation difficulties, concerns about confidentiality in small communities, and a scarcity of specialized providers (Rural Health Information Hub, 2024; Pullen & Oser, 2014). Compounding these logistical challenges is the pervasive social stigma surrounding addiction and mental health issues in Poland, which often manifests more acutely in smaller communities (Okulicz-Kozaryn & Marmot, 2018). The fear of judgment frequently deters individuals from seeking assistance at dedicated addiction facilities, even when such services are theoretically available (Luty, 2003; Crapanzano et al., 2019). This centralized model, while offering intensive care for those who access it, fails to leverage the potential of more accessible, community-based healthcare providers who could significantly expand the reach of addiction services.

Among these underutilized resources, pharmacists represent a particularly promising opportunity for policy innovation. With a network exceeding 13,000 community pharmacies across Poland, many situated in precisely the underserved areas where specialized addiction services are scarce, pharmacists maintain frequent contact with patients who may otherwise remain disconnected from the healthcare system (Naczelna Izba Aptekarska [NIA], 2023). The Polish healthcare system, primarily funded through the National Health Fund (Narodowy Fundusz Zdrowia, NFZ), has traditionally limited pharmacist roles to medication dispensing, but this paradigm is gradually evolving toward a more comprehensive care model (Gaciong & Grodzicki, 2020).

Recent health system reforms, notably the "Pharmacy for the Patient" (Opieka Farmaceutyczna) initiative formalized through the 2020 Act on the Profession of Pharmacist, signal a promising shift toward expanding pharmacists' clinical responsibilities (Dz.U. 2020 poz. 944). This legislation establishes the legal framework for pharmacists to provide services beyond traditional dispensing, including medication reviews, pharmaceutical consultations, adult vaccination administration, and health promotion programs (Merks et al., 2021; NIA, 2022). While the full implementation and reimbursement models for these services continue to develop through phased rollout (Jasińska-Stroschein et al., 2022), this evolution acknowledges the enhanced capabilities of contemporary pharmacy practice. However, a significant policy opportunity remains unexploited when comparing Poland's approach to several other nations that have successfully integrated pharmacists into their addiction support infrastructure.

Scotland's model demonstrates the potential for community pharmacists to serve as integral components of addiction care networks. For over two decades, Scottish pharmacists have been central to Opioid Substitution Therapy (OST) delivery, dispensing methadone and buprenorphine while supervising consumption for numerous patients under the National Health Service (Scottish Government, 2021; Matheson et al., 2011). Their role extends to critical harm reduction initiatives through needle and syringe programs and naloxone distribution, contributing substantially to Scotland's strategy for reducing drug-related mortality (Public Health Scotland, 2023). Evaluations consistently demonstrate this model's effectiveness in improving access, ensuring continuity of care, and reducing treatment stigma (Parkes et al., 2019).

Canada's response to its opioid crisis further illustrates the potential for pharmacy-based interventions. In provinces like British Columbia and Ontario, pharmacists have assumed expanded roles in addiction care as key providers of Opioid Agonist Treatment (OAT), often working collaboratively with prescribers or under specific protocols that permit dose adjustments, renewals, and in some jurisdictions, even treatment initiation for certain patients (College of Pharmacists of British Columbia, 2023; Ontario College of Pharmacists, 2022). Canadian pharmacists also play a vital role in naloxone distribution (both injectable and nasal formulations) without prescription requirements, while providing essential education on overdose prevention and response—a program implemented nationwide since the mid-2010s with ongoing refinements (Canadian Pharmacists Association, 2023; Health Canada, 2022).

Australia similarly demonstrates successful integration of pharmacists into its Opioid Dependence Treatment (ODT) Program, with pharmacists dispensing medications including methadone, buprenorphine, and buprenorphine-naloxone, often under supervised dosing arrangements (Australian Government Department of Health and Aged Care, 2023). Their participation in the National Naloxone Program, which provides subsidized or free naloxone through pharmacies to at-risk individuals, has shown increasing uptake in recent years (Pharmaceutical Society of Australia, 2022; Olsen et al., 2020). These programs have generally proven effective in expanding treatment access, though challenges persist in rural service provision and workforce capacity (Savic et al., 2017).

These international examples, supported by systematic reviews confirming pharmacists' effectiveness in improving SUD treatment access, medication adherence, and harm reduction outcomes (Bach & Goad, 2015; Kòmínda et al., 2020), highlight a significant missed opportunity within Polish healthcare policy. While the "Pharmacy for the Patient" initiative establishes important groundwork, its current implementation does not yet encompass specialized addiction support functions such as naloxone distribution (comparable to programs like New Jersey's pharmacy-based naloxone access initiative (NJ Human Services, 2023)), comprehensive SUD screening using validated instruments (e.g., AUDIT, DUDIT), brief interventions, or collaborative management of Medication-Assisted Treatment (MAT).

MAT, which includes evidence-based pharmacotherapies such as buprenorphine, naltrexone, and methadone, has demonstrated effectiveness for treating opioid use disorder and, for specific medications like naltrexone or acamprosate, alcohol use disorder (CDC, 2024; NIDA, 2023; WHO, 2020). Integrating pharmacists into MAT delivery and management, as successfully implemented in other countries, could dramatically improve treatment access throughout Poland, particularly in underserved regions (Radley et al., 2021). The current lack of formal integration represents a failure to capitalize on an existing healthcare workforce that could significantly help bridge the treatment gap and reduce the burden of SUDs, including prevalent alcohol use disorders and emerging concerns around stimulant and prescription drug misuse (EMCDDA, 2023a).

Even programs focused on supporting pharmacists' own well-being and recovery from addiction (California State Board of Pharmacy, 2023; Pharmacy Practice News, 2019) demonstrate the profession's inherent understanding and potential capacity to engage with addiction issues more broadly, if provided with adequate training, support, and policy frameworks. A comprehensive policy approach that formally integrates pharmacists into Poland's addiction treatment infrastructure represents a cost-effective, evidence-based strategy to address the current treatment gap while building upon existing healthcare reform initiatives.

International Models of Pharmacist-Led Addiction Support

The escalating global burden of substance use disorders (SUDs) necessitates innovative and accessible treatment and support models. Pharmacists, as highly accessible healthcare professionals, are increasingly recognized for their potential to play a pivotal role in addiction services. Their frequent patient interactions, medication expertise, and community presence position them uniquely to deliver harm reduction services, manage medication-assisted treatments (MAT), and facilitate referrals to specialized care. This chapter explores prominent international models where pharmacists are integral to national and regional addiction support strategies, highlighting their impact, key operational elements, the broader policy implications, and addressing challenges and areas for development.

Scottish Model: Pharmacy-Based Harm Reduction

Scotland has been at the forefront of integrating community pharmacies into its national addiction services strategy, primarily focusing on harm reduction for individuals who use drugs. The country's approach leverages the accessibility of pharmacies to deliver crucial interventions. While precise, nationally representative recent figures for specific service uptake can vary by health board and reporting period, reports from bodies like Public Health Scotland have historically indicated high engagement. For instance, a significant majority of Scottish community pharmacies have been involved in needle exchange programs (NEPs), and a large proportion provide supervised consumption services for opioid substitution therapy (OST) (Public Health Scotland, 2021). An earlier evaluation, often cited in policy discussions, suggested that pharmacy-based services had achieved high reach among people who inject drugs (PWID), contributing to public health goals such as reductions in HIV transmission rates and fatal overdoses (Scottish Government National Forum on Drug-Related Deaths, 2019).

The Scottish Government's national drug strategy, "Rights, Respect and Recovery," emphasizes a public health approach, with pharmacies playing a crucial role in delivering low-threshold services (Scottish Government, 2018). These services aim to reduce drug-related harm and improve the health and well-being of individuals affected by substance use. The high engagement of pharmacies in providing OST, often with supervised consumption, aims to ensure adherence and reduce the risk of medication diversion (World Health Organization/UNODC/UNAIDS, 2004; Mattick et al., 2014). The COVID-19 pandemic prompted adaptations, such as less frequent pick-ups and reduced supervised consumption in some cases, to balance infection control with continuity of care, with ongoing evaluation of these changes (Scottish Drugs Forum, 2021).

The Scottish model's success rests on several key policy foundations. Standardized training programs for pharmacists in addiction medicine equip them with the necessary knowledge and skills in addiction, harm reduction, and communication vital for effective service delivery (NHS Education for Scotland, 2022). This aligns with findings that pharmacists require adequate support and training to confidently provide OUD preventive services (Wu et al., 2024; ATTC Network, 2024). Integration with electronic health records (EHR) facilitates better care coordination, medication management, and communication between pharmacists, general practitioners, and specialist addiction services, though full interoperability remains a goal (NHS Digital Services, 2023).

Clear referral pathways to specialized services ensure that while pharmacists provide frontline support, individuals can access more intensive treatment and psychosocial support when needed (Scottish Government, 2018). Perhaps most critically from a policy perspective, Scotland has implemented a remuneration structure that recognizes addiction support as a core pharmacy service, providing appropriate funding and reimbursement models essential to sustain pharmacist involvement (Community Pharmacy Scotland, 2023).

Despite its successes, policy challenges include maintaining consistent service quality and coverage across all pharmacies, particularly in more remote areas. Pharmacist workload, potential burnout, and the need for ongoing training to address evolving drug use patterns (e.g., polysubstance use, synthetic opioids) are significant considerations (Galbraith & Pharmaceutical Journal, 2022). Stigma, both perceived by patients and potentially held by some staff, can also be a barrier, although efforts are made to promote a non-judgmental approach (Scottish Government, 2018). Community acceptance of harm reduction services, while generally good, can sometimes face localized resistance, requiring ongoing public health messaging (Drug Misuse and Dependence UK, 2020). Furthermore, ensuring robust coordination with broader addiction treatment and social services remains an ongoing priority to address the complex needs of individuals with SUDs (Recovery Answers, n.d.).

Canadian Opioid Stewardship Initiative

Canada has faced a severe opioid crisis, prompting multifaceted policy responses where pharmacists have emerged as essential partners. The Canadian model, particularly evident in provinces like British Columbia (BC) and Alberta, has progressively expanded the scope of practice for pharmacists through deliberate policy reform. In these provinces, pharmacists possess prescribing authority for opioid agonist treatment (OAT) (e.g., buprenorphine/naloxone, methadone) and naloxone, the opioid overdose reversal medication, under specific conditions and often following specialized training (College of Pharmacists of British Columbia, 2023; Alberta College of Pharmacy, 2023). This policy innovation aims to lower treatment thresholds and improve timely access to care (Gomes et al., 2018; Nosyk et al., 2016).

A study published in the Canadian Pharmacists Journal highlighted that pharmacy-based naloxone distribution programs significantly increased access to this life-saving medication, particularly in rural and remote communities where pharmacy access may be the primary healthcare touchpoint (Jones et al., 2019). Naloxone is a crucial emergency intervention (National Institute on Drug Abuse, 2022), and expanding access through various distribution strategies, including pharmacies, is a key public health policy goal (Canadian Agency for Drugs and Technologies in Health, 2021; Leece et al., 2020). The COVID-19 pandemic further underscored the value of accessible pharmacy services, with some jurisdictions implementing emergency policies to ensure continued access to OAT and naloxone, including telehealth consultations involving pharmacists (Brothers et al., 2022).

The Canadian model emphasizes collaborative practice agreements and pharmacist prescribing authority, which facilitate pharmacist prescribing and management of OAT, allowing for more flexible and responsive patient care, though implementation varies by province (Canadian Pharmacists Association, 2022). Pharmacist authority to prescribe and adjust MAT significantly improves access to treatment. Improved MAT retention, potentially facilitated by pharmacist involvement, can increase abstinence and decrease return to use (Socias et al., 2021; Volkow et al., 2014).

Community pharmacy-based screening and brief intervention (SBI) protocols are increasingly encouraged to identify individuals at risk and provide brief interventions or referrals, though systematic implementation varies across provinces (Pottie et al., 2019). Recognizing the social determinants of health, policy efforts are made to connect individuals with broader supports, though this integration can be challenging to implement consistently (Public Health Agency of Canada, 2023a).

Canada continues to experience high rates of opioid-related harms. In the first half of 2023, there were 3,556 apparent opioid toxicity deaths, with rates remaining high (Public Health Agency of Canada, 2023b). Provinces like BC have implemented innovative policies such as prescribed safer supply, where pharmacists are involved in dispensing alternatives to the toxic illicit drug supply, a strategy that is subject to ongoing debate and evaluation (Government of British Columbia, 2023; Canadian Medical Association Journal, 2023).

While pharmacist prescribing authority is a significant policy advancement, its uptake and implementation vary across provinces, creating a patchwork of access (Gomes et al., 2021). Policy challenges include ensuring adequate pharmacist training, support for complex cases, managing increased workload, and fostering seamless integration with primary care and specialist addiction services. Some critics raise concerns about the potential for increased diversion if prescribing safeguards are not robust, and the need for careful monitoring of prescribing practices (Persaud, 2020). Ethical considerations around prescribing controlled substances in a community pharmacy setting also warrant ongoing policy discussion (Journal of Ethics in Mental Health, 2019).

Australian Rural Pharmacy Network Support Program

Australia has recognized the unique challenges in providing addiction support to rural and underserved communities through targeted policy initiatives. Programs funded under various initiatives aim to enhance training and resources for pharmacists serving remote populations (Pharmaceutical Society of Australia, 2022a). Evaluations of such rural pharmacy initiatives have generally indicated positive impacts on service delivery, such as improved identification of at-risk individuals and better linkage to care, compared to areas without such enhanced support (Australian Journal of Rural Health, 2021). Pharmacists in rural areas often play a more extended role due to the scarcity of other healthcare providers, a reality that policy must acknowledge and support (National Rural Health Alliance, 2023).

Australia's National Drug Strategy 2017–2026 emphasizes harm minimization through a three-pillar approach addressing demand, supply, and harm reduction (Australian Government Department of Health and Aged Care, 2017). Pharmacists contribute significantly, particularly to harm reduction (e.g., needle and syringe programs, naloxone provision) and facilitating access to treatment (Pharmaceutical Society of Australia, 2022b). The Pharmaceutical Society of Australia (PSA) advocates for expanded roles, including managing OST and administering injectable pharmacotherapies, with recent trials and rollouts of long-acting injectable buprenorphine involving pharmacists (Pharmaceutical Society of Australia, 2023).

Key elements of Australian rural pharmacy support include targeted training and resources for rural pharmacists addressing specific rural practice needs, including managing limited local specialist services and understanding unique community dynamics (CRANAplus, 2022). Enhanced capacity for early identification and intervention is developed by training pharmacists in screening tools and brief intervention techniques (Australian Primary Health Care Nurses Association, 2020). Pharmacists act as crucial first points of contact, bridging gaps to distant specialist services, with evidence suggesting that pharmacist-led care transitions can improve treatment retention (Shanahan et al., 2021). Creating networks among rural pharmacists and utilizing telehealth can reduce professional isolation and improve access to specialist advice (Rural Doctors Association of Australia, 2023).

From a policy perspective, sustaining enhanced pharmacy services in rural areas requires ongoing and specific funding mechanisms. Attracting and retaining pharmacists in these regions remains a persistent challenge requiring targeted workforce policies (National Rural Health Alliance, 2023). Ensuring equitable access to a full spectrum of addiction treatments, beyond what a pharmacy can solely provide, necessitates strong linkages with other health and social services, which are often sparse in rural areas (Australian Institute of Health and Welfare, 2022b). There can also be community resistance to establishing certain harm reduction services in smaller towns, requiring careful community engagement strategies (Australian Injecting & Illicit Drug Users League, 2021). The cost-effectiveness of specific rural pharmacy interventions needs robust local evaluation to guide policy investment decisions (Deeble Institute for Health Policy Research, 2020).

Emerging Model: Pharmacist Involvement in Addiction Services in South Africa

While not as extensively documented in terms of national, pharmacist-led addiction treatment models like those in Scotland or Canada, pharmacists in South Africa are increasingly recognized in policy discussions for their potential role, particularly in harm reduction and supporting adherence to treatment for co-occurring conditions like HIV and TB, which are prevalent among people who use drugs (Pan African Medical Journal, 2020). South Africa faces significant challenges with substance use, including opioids, methamphetamine (tik), and alcohol (South African Medical Research Council, 2022).

Pharmacists are highly accessible healthcare providers in many South African communities. Their role in providing HIV testing, counseling, and medication adherence support offers a platform for integrating SUD screening and brief interventions (World Health Organization, 2021). Some non-governmental organizations (NGOs) partner with community pharmacies for needle and syringe programs or to improve access to information about addiction services (TB HIV Care, 2023). The South African Pharmacy Council has outlined competencies that include public health promotion, which can encompass addiction awareness and harm reduction advice (South African Pharmacy Council, 2019).

The potential for expanding pharmacist roles in addiction services in South Africa is considerable, especially for screening, brief interventions, naloxone distribution (where policy allows), and supporting MAT linkage. However, policy challenges include a need for more structured training in addiction for pharmacists, regulatory frameworks to support expanded roles (e.g., naloxone provision without a prescription, OAT management), integration with a stretched public health system, and addressing stigma (International Journal of Drug Policy, 2022). Funding for such expanded services within pharmacies is also a major policy consideration. Patient perspectives often highlight the convenience of pharmacies but also concerns about privacy and stigma, similar to other contexts (Journal of Substance Abuse Treatment, 2021).

Cross-Cutting Themes and Innovations

Across these models, digital health and telehealth are emerging as important policy considerations. During the COVID-19 pandemic, telehealth consultations facilitated remote prescribing and counseling for OAT, with pharmacists playing a role in dispensing and follow-up (SAMHSA, 2021; European Monitoring Centre for Drugs and Drug Addiction, 2022). Apps for medication reminders, recovery support, and virtual peer groups are also being explored, with potential for pharmacy integration in promoting these tools (Journal of Medical Internet Research, 2023).

While much policy focus has been on opioids, pharmacists are also positioned to address polysubstance use and alcohol use disorder (AUD). This includes screening for alcohol misuse, providing brief interventions, offering advice on reducing alcohol-related harm, and managing medications for AUD (e.g., naltrexone, acamprosate) where protocols and training allow (National Institute on Alcohol Abuse and Alcoholism, 2022). The complexity of polysubstance use requires enhanced pharmacist training in identifying interactions and tailoring advice (Substance Abuse and Mental Health Services Administration, 2023).

A common thread across successful models is the critical need for comprehensive education and training for pharmacists in addiction medicine, harm reduction, trauma-informed care, and culturally sensitive communication (International Pharmaceutical Federation, 2021). This should extend beyond initial qualification to include ongoing professional development, a consideration that policy must address.

Incorporating patient perspectives is crucial for designing effective and acceptable services. Studies indicate that patients value the accessibility and convenience of pharmacies but may have concerns about privacy, stigma, and the time available for consultation (Gryczynski et al., 2018; Canadian Centre on Substance Use and Addiction, 2022). Co-designing services with people with lived and living experience can improve engagement and outcomes (Harm Reduction Journal, 2023).

Evidence-Based Approaches and Current Policy Challenges

The international models discussed highlight several evidence-based approaches central to effective addiction support. Opioid Agonist Treatment (OAT) remains a cornerstone of treatment for opioid use disorder, effectively delivered and supervised in pharmacy settings (UNODC, 2004; Mattick et al., 2014). Lowering treatment thresholds through pharmacy access can improve outcomes (Nosyk et al., 2016). Pharmacy-based naloxone programs significantly increase access, empowering individuals to respond to overdoses (National Institute on Drug Abuse, 2022; LDI Penn, 2019). Needle and Syringe Programs (NSPs) are proven to reduce blood-borne virus transmission (MacArthur et al., 2015). Harm reduction approaches, including drug checking services (where available), safer use education, and access to sterile equipment, are increasingly recognized in policy (SAMHSA, 2023). Pharmacists are well-positioned for Screening, Brief Intervention, and Referral to Treatment (SBIRT) (Babor et al., 2007).

Despite successes, several current challenges in addiction policy implementation persist globally. Stigma remains a major barrier for individuals seeking help and for healthcare provider engagement (Livingston et al., 2012). Sustainable funding models that adequately compensate pharmacists for expanded roles are crucial (ATTC Network, 2024; Pharmaceutical Group of the European Union, 2021). The cost-effectiveness of pharmacy-led interventions is an important advocacy point, often demonstrating savings in downstream healthcare costs (UK Department of Health and Social Care, 2017).

Restrictive regulations limit pharmacists' ability to provide comprehensive support in many jurisdictions, though some are modernizing (International Pharmaceutical Federation, 2022). Ensuring pharmacists have necessary skills and ongoing development is essential to policy success (Wu et al., 2024). Improving collaboration between pharmacies, primary care, specialist services, and social supports remains key (Recovery Answers, n.d.). This includes better data sharing and referral protocols.

Robust data collection is needed to monitor outcomes, identify best practices, and adapt to evolving needs, such as the rise of potent synthetic opioids and stimulants, and polysubstance use (European Monitoring Centre for Drugs and Drug Addiction, 2023). Expanded roles, particularly in prescribing or direct supply of addiction treatments, require careful consideration of ethical guidelines and potential conflicts of interest, ensuring patient well-being remains paramount (Journal of Bioethical Inquiry, 2020).

While many communities support these services, some may exhibit "Not In My Backyard" (NIMBYism) attitudes towards harm reduction facilities, including those in pharmacies. Addressing this requires public education and community engagement strategies (Strike et al., 2006).

Unique Challenges and Opportunities in the Polish Context

Poland's healthcare landscape presents a distinctive framework for implementing a pharmacist-initiated addiction support network. With 12,161 general access pharmacies operating at the end of 2022 (Główny Inspektorat Farmaceutyczny, 2023), Poland enjoys a pharmacy density of approximately one pharmacy per 3,120 inhabitants—higher than the EU average of one per 3,200 inhabitants (Pharmaceutical Group of the European Union, 2023). This extensive network offers unparalleled reach into rural and underserved communities where specialized healthcare services, including addiction treatment, are often limited (World Health Organization, 2021).

The prevalence of substance use disorders (SUDs) in Poland underscores the urgent need for enhanced support systems. According to the State Agency for the Prevention of Alcohol-Related Problems, approximately 700,000-900,000 people were addicted to alcohol in 2021, with around 2.5 million people drinking alcohol harmfully (PARPA, 2022). While high-risk opioid use prevalence in Poland remains relatively low at 0.27 per 1,000 population aged 15-64 (EMCDDA, 2023a), problematic use of stimulants, cannabis, and new psychoactive substances continues to present significant public health challenges. The current addiction treatment infrastructure exhibits concerning regional disparities and often lengthy waiting times for specialized services (EMCDDA, 2023a). Research on drug treatment patients' rights in Poland has highlighted inconsistent experiences across different specialist settings, indicating a pressing need for standardized, patient-centered approaches (Ramon et al., 2017).

The economic burden of SUDs in Poland is substantial, encompassing direct healthcare costs, productivity losses, and social costs related to crime and family disruption. While comprehensive national figures are not consistently updated, various studies suggest these costs run into billions of PLN annually (Jakubczyk et al., 2013). This economic reality strengthens the case for innovative approaches to addiction treatment delivery.

Cultural attitudes toward addiction in Poland often reflect significant stigma and moralistic perspectives, creating major barriers to help-seeking (OKO.press, 2021; CBOS, 2019). Many individuals fear social judgment or discrimination, making them reluctant to disclose substance use issues even to healthcare professionals. Pharmacies, being highly accessible and relatively anonymous points of contact, could potentially lower this barrier if services are delivered discreetly and with cultural sensitivity. However, the public nature of many pharmacies and potential privacy limitations must be thoughtfully addressed in policy development (Świtalska & Brola, 2020).

Regulatory Framework Considerations

The current Polish Pharmaceutical Law (Prawo farmaceutyczne, 2001) primarily defines pharmacists' roles around medication dispensing, compounding, and providing basic pharmaceutical information. This framework does not explicitly authorize pharmacists to engage in broader public health interventions such as addiction screening, initiating SUD treatment, or comprehensive harm reduction service provision. Significant regulatory amendments would be necessary to legally empower pharmacists for these expanded roles.

Expanding the scope of practice to include screening for substance use disorders represents a crucial regulatory change. Currently, Polish pharmacists lack formal recognition and training to conduct systematic SUD screening. Amending the Pharmaceutical Law to include this role as part of broader pharmaceutical care services would align Poland with countries like the United Kingdom, where pharmacists participate in delivering public health services including brief interventions for alcohol (NHS England, 2022), and Canada, where some provinces have enabled pharmacists to play greater roles in mental health and addictions care (Canadian Pharmacists Association, 2021).

Authorizing pharmacists to dispense naloxone without a prescription would constitute another vital regulatory advancement. While Poland has increased naloxone distribution through low-threshold programs, pharmacy-based access without prescription is not standard practice (EMCDDA, 2023a). Poland's drug laws, outlined in the Act on Counteracting Drug Addiction (2005), generally focus on control and criminalization, though treatment provisions exist. Making naloxone directly available from pharmacies without prescription, as practiced in the United States, Canada, and parts of Europe, would represent a critical harm reduction measure aligned with principles emphasizing practical strategies to reduce negative consequences of substance use (NIDA, 2022; WHO, 2023).

Establishing protocols for supervised consumption and dispensing of opioid substitution therapy (OST) presents another regulatory opportunity. While OST is available in Poland, it typically comes from specialized treatment centers, serving around 2,800 clients in 2021 (EMCDDA, 2023a). In countries like the UK, Australia, and Canada, community pharmacies play vital roles in dispensing daily OST doses, often under supervision, increasing accessibility and normalizing treatment (Strang et al., 2020). Polish regulations would need adaptation to allow and standardize pharmacy-based OST dispensing, including clear protocols for supervision, record-keeping, collaboration with prescribing physicians, and ensuring patient confidentiality.

Creating privacy requirements for consultation spaces within pharmacies represents a necessary regulatory development. Current pharmacy layouts in Poland may not consistently offer adequate privacy for addiction-related conversations (Świtalska & Brola, 2020). Regulations mandating private consultation areas within pharmacies, as outlined in the Regulation of the Minister of Health on basic conditions for running a pharmacy (2002), would need strengthening and enforcement to foster trust and encourage help-seeking. This aligns with standard requirements for pharmacies offering advanced clinical services in many developed countries (Pharmaceutical Society of Ireland, 2023).

The strictness of Polish drug laws presents a contextual challenge for addiction policy reform. The Act on Counteracting Drug Addiction (2005) maintains criminal penalties for possession of even small amounts of illicit substances for personal use, though Article 62a allows for prosecutorial discretion in certain cases. This legal framework creates fear and stigma, potentially deterring individuals from seeking help (Społeczna Inicjatywa Narkopolityki, 2022). While a pharmacist-initiated support network focuses primarily on treatment access, the broader legal context significantly influences help-seeking behavior. Policy discussions should consider how public health-oriented approaches to personal drug possession could complement initiatives aimed at increasing care access, though proposals for decriminalization often face significant political opposition (EMCDDA, 2023b).

The political feasibility of these regulatory changes varies. Growing recognition of public health needs creates opportunities, but drug policy reform often encounters resistance from conservative elements. Support from medical and pharmaceutical associations, patient advocacy groups, and evidence from pilot programs would prove crucial for advancing these regulatory changes. Potential resistance from other healthcare professionals regarding scope of practice and care coordination would require clear role definitions, robust communication channels, and emphasis on collaborative approaches to patient care.

Healthcare Financing Implications

The National Health Fund (Narodowy Fundusz Zdrowia - NFZ) serves as Poland's primary public healthcare payer. Currently, its reimbursement model for pharmacies almost exclusively ties to medication dispensing (NFZ, 2023a; Gawron et al., 2020). For a pharmacist-initiated addiction support network to achieve viability and sustainability, this model must evolve to include remuneration for cognitive services and public health interventions.

Creating billing codes for addiction screening and brief interventions represents a fundamental financing requirement. The NFZ would need to establish specific codes allowing pharmacists to claim reimbursement for conducting validated SUD screenings and delivering brief interventions. This aligns with the introduction of "pharmaceutical care" (opieka farmaceutyczna) services, for which legislative groundwork exists but full implementation and funding mechanisms continue developing (Naczelna Izba Aptekarska, 2023). Countries like the United States, through Medicare and Medicaid, have established pathways for reimbursing healthcare providers for Screening, Brief Intervention, and Referral to Treatment (SBIRT) services (SAMHSA, n.d.a), offering potential models for Polish adaptation.

Developing reimbursement mechanisms for harm reduction supplies and services constitutes another essential financing component. If pharmacists are to dispense naloxone or other harm reduction supplies, the NFZ or other public funds must cover both supply costs and associated counseling services. The cost of drug programs in Poland represents a significant concern for the NFZ, which employs various instruments to reduce public expenditure on reimbursement (Gawron et al., 2020). Therefore, new reimbursements must be justified by potential long-term savings from reduced healthcare crises, overdose fatalities, and improved public health outcomes.

Financial incentives for pharmacies serving high-need communities would promote equitable access to addiction services. Pharmacies in rural or socioeconomically disadvantaged areas, which may face higher demand for addiction support services amid fewer existing resources, could receive support through enhanced reimbursement rates or grants. This approach would help ensure equitable service provision, addressing potential "pharmacy deserts" for specialized services even where physical pharmacy access remains generally good (Qato et al., 2024).

Integration with existing addiction treatment funding streams would enhance system coherence. Funding for pharmacist-led services should integrate with, rather than operate separately from, existing national and regional addiction treatment budgets managed by the NFZ (NFZ, 2023b). This would ensure a coordinated approach and leverage existing financial frameworks. The NFZ's financial plan for healthcare services (NFZ, 2023a) would require adaptation to incorporate these new pharmacist roles, ensuring smooth financial and administrative transitions for referred patients.

Pharmacists themselves have expressed concerns about workload, the need for adequate compensation for new services, and potential liability issues (Kowalski & Nowak, 2022). These legitimate concerns must be addressed through fair remuneration models and clear legal and professional guidelines to ensure widespread professional engagement with expanded addiction support roles.

Professional Capacity Building Needs

While many Polish pharmacists may express willingness to engage in addiction support, a significant gap often exists between willingness and preparedness. For instance, while not specific to addiction, surveys on new pharmaceutical care services frequently indicate a need for further training (Naczelna Izba Aptekarska, 2022). If a survey similar to one previously mentioned (78% willing, 12% prepared) were confirmed for addiction services, it would highlight a critical need for comprehensive professional development.

Developing specialized addiction medicine modules in pharmacy education represents a foundational capacity-building approach. Undergraduate pharmacy curricula should incorporate comprehensive modules on addiction science, pharmacology of psychoactive substances, SUD assessment tools, motivational interviewing techniques, evidence-based treatment modalities, harm reduction principles, and culturally sensitive communication. This knowledge foundation is essential for preparing future pharmacists for expanded addiction support roles.

Continuing education requirements for practicing pharmacists would address immediate workforce needs. Mandatory continuing professional development programs focused on addiction should be implemented for all practicing pharmacists. These could be delivered through accredited online modules, workshops, and seminars, potentially in collaboration with addiction treatment centers or academic institutions. Organizations like the American Society of Addiction Medicine provide resources for certification and education that could serve as models for developing Polish equivalents (ASAM, n.d.).

Mentorship programs pairing pharmacists with addiction specialists would enhance practical competence. Establishing programs where experienced addiction specialists guide and support pharmacists entering this new role could significantly enhance their confidence and competence through case discussions, shadowing opportunities, and ongoing support. The Grayken Center for Addiction Training and Technical Assistance at Boston Medical Center offers a model for such capacity building (Boston Medical Center, n.d.) that could be adapted to the Polish context.

Creating a certification pathway for addiction services would ensure quality and standardization. Developing a voluntary or mandatory certification pathway for pharmacists specializing in addiction support could ensure standardized expertise and care quality. This could involve completing accredited training programs and passing competency assessments, similar to addiction medicine certifications available for physicians (ASAM, n.d.). The CDC's training on SUD treatment could inform such certification content (CDC, 2024).

Expanding pharmacists' roles brings implementation challenges that require thoughtful policy consideration. Physical environment limitations in many pharmacies may impede private consultations about sensitive topics. Time constraints faced by busy pharmacists present another practical barrier. Furthermore, some individuals with SUDs may remain hesitant to discuss these issues in pharmacy settings, preferring specialized clinics (Lisiecki et al., 2021). Potential unintended consequences include overburdening pharmacists without adequate support or creating inconsistent care if training and implementation lack standardization. Implementation science principles, focusing on systematic uptake of evidence-based practices into routine care, would prove crucial for navigating these complexities and ensuring successful policy transfer (Bauer et al., 2015).

Recent developments in Polish healthcare, including ongoing implementation of "opieka farmaceutyczna" and lessons from the COVID-19 pandemic (which saw expanded pharmacist roles in vaccinations), may create a more receptive environment for further expanding pharmacists' public health responsibilities (Ministerstwo Zdrowia, 2023).

Implementing these changes requires a multi-faceted approach involving legislative action, financial restructuring within the NFZ, and significant investment in professional development and inter-professional collaboration. However, leveraging Poland's dense pharmacy network offers a unique opportunity to significantly improve addiction support access, reduce harm, and better integrate addiction care into the broader healthcare system. This transformation must proceed thoughtfully, addressing potential barriers and ensuring the model benefits both pharmacists and the individuals they aim to serve. With proper policy development, Poland's pharmacy network could become a powerful asset in addressing the nation's substance use challenges while creating a model for other countries facing similar public health needs.

Proposed Model for Poland: A Comprehensive Pharmacist-Initiated Addiction Support Network

The development of a comprehensive addiction support network initiated by pharmacists in Poland holds significant promise for enhancing public health outcomes. This model aims to leverage the accessibility and trust associated with community pharmacies to provide a spectrum of services, from prevention to recovery support. However, successful implementation requires careful consideration of Poland's specific cultural attitudes towards addiction, which can include significant stigma and moralistic viewpoints (Okulicz-Kozaryn & Turska-Kawa, 2019), the existing healthcare financing system, and potential interprofessional dynamics. The following sections detail the core components and implementation strategy for such a network, drawing on international best practices, evidence-based approaches, and an updated understanding of the Polish context, including its significant challenge with alcohol use disorders (World Health Organization [WHO], 2018; European Monitoring Centre for Drugs and Drug Addiction [EMCDDA], 2023b).

Core Service Components

The proposed Pharmacist-Initiated Addiction Support Network would include four tiers of service, designed to offer a continuum of care and support for individuals at various stages of substance use and recovery.

Tier 1: Universal Prevention and Screening

Universal prevention and screening efforts form the foundational tier of this model, aiming to identify individuals at risk, provide early intervention, and educate the public. Pharmacies, as highly accessible healthcare points, are uniquely positioned to deliver these services.

Pharmacists can be trained to administer brief, validated screening tools such as the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C) for identifying hazardous drinking or active alcohol use disorders (Bush et al., 1998), which is particularly relevant given Poland's high rates of alcohol consumption (WHO, 2018). Similarly, the Drug Abuse Screen Test (DAST-10) can effectively screen for problematic drug use (Skinner, 1982; National Institute on Drug Abuse [NIDA], 2023a). While these tools are established, newer instruments or those specifically validated in Polish populations should also be considered (Gmel et al., 2001). Integration into routine pharmacy interactions aligns with the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model (Babor et al., 2007).

In Poland, alcohol-related mortality and morbidity are significant concerns (EMCDDA, 2023b). Early identification via pharmacy screening could be crucial. While UK studies show feasibility for alcohol screening in pharmacies (Dhital et al., 2010), and Canadian pharmacists screen for various conditions (Kennie-Kaulbach et al., 2017), the Polish context requires specific adaptation. The need for accessible early intervention in Poland has been noted (EMCDDA, 2023b), and pharmacies could contribute if adequately supported and if pharmacists are trained in culturally sensitive communication to mitigate stigma (Okulicz-Kozaryn & Turska-Kawa, 2019).

Comprehensive medication reviews conducted by pharmacists can identify patterns indicative of prescription drug misuse, such as early refills or multiple prescribers. The misuse of prescription opioids, sedatives, and stimulants is a global concern (NIDA, 2023b). Medication Therapy Management (MTM) services in the US have shown utility in detecting such problems (American Pharmacists Association & National Association of Chain Drug Stores Foundation, 2008). In Poland, while illicit drug data is more prominent, vigilance regarding prescription drug misuse is vital. The Polish Pharmaceutical Law (Journal of Laws 2021, item 1977) mandates pharmaceutical care, which provides a foundation. However, the law's current scope may require clarification or expansion to explicitly cover advanced monitoring for SUDs and intervention, as pharmacists' roles are more traditionally defined (Świeczkowski et al., 2021).

Pharmacies can serve as critical distribution points for evidence-based information on substance use risks, harm reduction, and treatment options. NIDA emphasizes applying scientific knowledge to improve health (NIDA, n.d.). Materials should cover common substances, overdose risks, naloxone benefits, and treatment access, tailored to address specific Polish concerns like high alcohol consumption and emerging drug trends (EMCDDA, 2023a). Increasing public awareness and reducing stigma are crucial in Poland (Mravčík et al., 2017; Okulicz-Kozaryn & Turska-Kawa, 2019). While harm reduction programs exist in Poland, pharmacy-based dissemination could improve reach (Glabinski et al., 2017). Australian pharmacies successfully distribute health promotion materials (Pharmaceutical Society of Australia, 2019), offering a potential model.

Safe medication disposal in pharmacies prevents diversion, accidental poisoning, and environmental contamination (U.S. Environmental Protection Agency [EPA], 2023). Many countries have pharmacy take-back programs (DEA, n.d.). In Poland, a standardized, widely promoted national program for medication disposal through pharmacies could significantly enhance current, often ad-hoc, efforts. This aligns with public health goals of reducing unused controlled substance availability, a concern previously noted in the Polish context (Polish Drug Policy Network, 2012).

Tier 2: Harm Reduction Services

Harm reduction aims to minimize negative impacts associated with drug use and policies (Harm Reduction International, n.d.). Pharmacies can be key sites, though this requires navigating Poland's legal and political landscape, which may present barriers or require advocacy (EMCDDA, 2023b).

Needle and syringe programs (NSPs/NEPs) reduce blood-borne virus transmission (e.g., HIV, HCV) among people who inject drugs (PWID) (WHO, 2020; Wodak & Cooney, 2006). While some countries like France (Carrieri et al., 2000) and Australia (Australian Government Department of Health and Aged Care, 2023) have successfully integrated NSPs into pharmacies, implementation is not universally smooth and often faces barriers like pharmacist reluctance or logistical challenges (Amundstuen et al., 2021; Watson et al., 2012). In Poland, existing harm reduction programs, including NEPs, have limited coverage (Glabinski et al., 2017; EMCDDA, 2023b). Expanding NSPs via pharmacies could increase access, especially given HCV prevalence among PWID in Poland (EMCDDA, 2023b). However, legal frameworks in Poland may need explicit clarification or amendment to fully support pharmacy-based NEPs, and potential opposition from conservative elements needs to be considered (Ritter & Cameron, 2006).

Naloxone reverses opioid overdose and is critical for preventing deaths (WHO, 2023). Pharmacists can dispense naloxone (often via standing orders or similar protocols in other countries) and train on its use. Many US states have pharmacy-based naloxone programs (e.g., Walley et al., 2013; NJ Department of Human Services, n.d.). In Poland, the number of drug-induced deaths reported by the EMCDDA (2023b) was 206 in 2021. Enhancing naloxone availability through pharmacies is crucial, especially with concerns about new psychoactive substances (EMCDDA, 2023a). The legal basis for Polish pharmacists to dispense naloxone without a patient-specific prescription needs careful examination and likely legislative support.

Fentanyl test strips (FTS) detect fentanyl in illicit drugs, aiding overdose prevention (Peiper et al., 2019; Krieger et al., 2018). While fentanyl prevalence in Poland's drug supply is currently lower than in North America (EMCDDA, 2023a), preparedness is vital. Offering FTS and other supplies (sterile water, swabs) via pharmacies would be comprehensive. This proactive approach must be balanced with local drug market realities and potential political sensitivities in Poland.

Pharmacies can offer anonymous/confidential health monitoring (e.g., blood pressure, rapid HIV/HCV tests). Substance use and infectious diseases often co-occur (NIDA, 2020). Pharmacies could lower access barriers in Poland, especially for stigmatized groups (Glabinski et al., 2017). Integrating such services, as seen in the UK's Healthy Living Pharmacy framework (NHS England, n.d.), could improve early diagnosis if implemented with cultural sensitivity and guarantees of anonymity.

Tier 3: Treatment Support

Pharmacists can significantly support individuals in addiction treatment, particularly medication-assisted treatment (MAT) or medications for opioid use disorder (MOUD).

Opioid substitution therapy (OST) using methadone or buprenorphine is evidence-based (WHO et al., 2004; Substance Abuse and Mental Health Services Administration [SAMHSA], 2024a). Supervised consumption by pharmacists improves adherence and reduces diversion (Mattick et al., 2014). This is established in the UK (Pharmaceutical Services Negotiating Committee, n.d.), Australia (Pharmacy Programs Administrator, 2023), and Canada (College of Pharmacists of British Columbia, 2017). In Poland, OST access and coverage are challenging (Gedeon et al., 2018). Pharmacy-based supervised consumption could expand access, but this would require clear regulatory frameworks, pharmacist training, and reimbursement models through the National Health Fund (NFZ). Lowering treatment thresholds is key (Bell et al., 2016; Strang et al., 2015).

Adherence to SUD medications (e.g., naltrexone, acamprosate for AUD; MOUD) is vital (SAMHSA, 2024a; U.S. Food and Drug Administration [FDA], 2023). Pharmacists can use counseling, dose aids, and motivational interviewing (Nieuwlaat et al., 2014). This is especially important for Poland's prevalent AUDs. Pharmacists can reinforce MAT's combination of medication and behavioral therapies (American Addiction Centers, 2024). Enhancing adherence support for Poland's OST patients could improve outcomes (Mravčík et al., 2017).

Effective treatment requires collaboration between pharmacists and prescribers. Pharmacists can report on adherence, side effects, and discuss adjustments. This interprofessional collaboration is crucial (Van Winkle et al., 2011). However, establishing such collaborative practices in Poland may face resistance from some medical professionals concerned about role encroachment (Zillich et al., 2004), requiring dialogue and clear protocols.

Pharmacies can be telehealth access points, connecting individuals with specialists, especially in underserved areas. The COVID-19 pandemic accelerated telehealth adoption for addiction treatment (SAMHSA, 2021), and its role remains significant post-pandemic (SAMHSA, 2022). This model could improve access in Poland, but requires infrastructure, privacy, and integration with existing e-health systems.

Tier 4: Recovery Support

Long-term recovery requires sustained support, and pharmacies can contribute significantly to this phase of addiction care.

Dedicated, private consultation spaces are essential for discussing recovery. These check-ins allow pharmacists to offer encouragement and monitor progress in a non-stigmatizing environment (White, 2009). This requires pharmacies to invest in appropriate infrastructure but can yield significant benefits for maintaining long-term recovery and preventing relapse.

Peer support is invaluable in recovery (SAMHSA, 2017). Pharmacists can navigate individuals to Polish peer support groups (e.g., AA, NA equivalents) and recovery organizations. Enhancing visibility and integration of these groups with formal healthcare in Poland is needed to create a more comprehensive recovery ecosystem that combines professional and peer-based approaches.

Individuals in recovery may use medications for sobriety (e.g., naltrexone for AUD) or co-occurring conditions (SAMHSA, 2024a). Pharmacists are key in monitoring for drug interactions, a core competency vital for safe recovery. This monitoring can prevent complications that might otherwise derail recovery efforts and represents an important safety mechanism within the broader addiction care system.

Addiction impacts families profoundly. Pharmacists can provide information and resources to family members, directing them to support services. Family involvement can be crucial (Copello et al., 2009). This holistic approach acknowledges the broader social context, which is particularly important in family-oriented cultures like Poland, where family support can be a critical factor in successful recovery outcomes.

Implementation Strategy

A phased approach is recommended, considering Poland's specific context, including potential political opposition to harm reduction and the need for financial sustainability within the NFZ system.

The pilot phase (Year 1) would establish 50 participating pharmacies across five voivodeships, prioritizing areas with limited addiction services and diverse demographics (urban/rural). This pilot would test feasibility and acceptability. Key activities include developing Polish-context-specific training (including cultural sensitivity and addressing stigma), data collection mechanisms, securing regulatory approvals/waivers (especially for harm reduction components), and strong stakeholder engagement (pharmacist associations, medical bodies, patient groups, Ministry of Health, NFZ) (Green et al., 2015). Addressing regional disparities in Poland is crucial (EMCDDA, 2023b). This phase must also assess and strategize for potential resistance from other healthcare professionals (Zillich et al., 2004).

The evaluation phase (Year 2) would assess outcomes and refine the model based on pilot data. A comprehensive evaluation using key performance indicators would include process indicators such as the number screened (disaggregated by substance type, e.g., alcohol), materials distributed, naloxone/NEP uptake (if legally feasible), and treatment support engagement. Outcome indicators would measure changes in substance use (especially alcohol), naloxone use in overdoses, MOUD/AUD medication adherence, patient/pharmacist satisfaction, referral rates, and impact on stigma (qualitative). Cost-effectiveness analysis is crucial for NFZ buy-in. Qualitative data from interviews with pharmacists, patients, and physicians will explore barriers (e.g., cultural, political, interprofessional) and facilitators (Glabinski et al., 2017). The evaluation should also consider if pharmacies become stigmatized and how to mitigate this risk.

The expansion phase (Years 3-4) would scale to 500 pharmacies nationwide based on positive evaluation, refined model, and secured funding pathways (e.g., NFZ contracts). This requires robust pharmacist training, quality assurance, and addressing workforce capacity (Fixsen et al., 2005). Lessons from scaling public health interventions in other European countries with similar healthcare structures would be valuable (Bauld et al., 2011). Strategies for navigating potential political opposition to certain services (e.g., harm reduction) will be critical during this phase.

Full implementation (Year 5) would integrate the model into standard pharmacy practice nationwide. This requires policy and regulatory changes, such as amending Polish Pharmaceutical Law (Journal of Laws 2021, item 1977) to clearly define and authorize expanded roles, especially for harm reduction and advanced treatment support. Sustainable remuneration models must be developed, with clear fee-for-service or capitation models via the NFZ or other public/private funds. Integration into pharmacy education would incorporate addiction science, harm reduction, motivational interviewing, and cultural competency into curricula and continuing professional development. Ongoing quality improvement through continuous monitoring and refinement would ensure the program remains effective and responsive to emerging needs.

Achieving full implementation necessitates strong political will, sustained funding, inter-agency collaboration (Ministry of Health, NFZ, pharmacist bodies, addiction service providers), and public awareness campaigns to build support and reduce stigma. Examples from Central/Eastern European countries that have expanded pharmacy roles would offer valuable insights (Horvat et al., 2020).

This proposed model, if implemented thoughtfully, with robust evaluation, and adapted to Poland's unique cultural, legal, and financial landscape, has the potential to significantly enhance the country's response to addiction, particularly the prevalent issue of alcohol use disorder, improve public health outcomes, and save lives. By leveraging the existing pharmacy infrastructure and the trusted position of pharmacists in communities, Poland can create a more accessible, comprehensive, and effective addiction care system that addresses the full continuum from prevention to long-term recovery.

Multi-Stakeholder Collaboration Framework

The complexity of addiction, spanning health, social, economic, and criminal justice domains, necessitates a coordinated response that transcends individual organizational capacities. A Multi-Stakeholder Collaboration Framework (MSCF) is crucial for developing and implementing effective addiction policies. Such frameworks pool resources, expertise, and perspectives, leading to more comprehensive, sustainable, and community-accepted solutions (World Health Organization [WHO], 2017).

Successful implementation hinges on robust coordination among diverse stakeholders, each playing a critical role. Globally, an estimated 296 million people used drugs in 2021, with approximately 39.5 million suffering from drug use disorders (United Nations Office on Drugs and Crime [UNODC], 2023). In the United States, an estimated 46.1 million people aged 12 or older had a substance use disorder (SUD) in 2022, including 29.5 million with alcohol use disorder and 27.2 million with a drug use disorder, yet only 23.7% of those with an SUD received any substance use treatment in the past year (Substance Abuse and Mental Health Services Administration [SAMHSA], 2023a). This significant treatment gap underscores the urgent need for collaborative efforts. The COVID-19 pandemic further exacerbated existing challenges, increasing substance use and overdose rates in many regions, while also spurring innovations in telehealth and service delivery models that require ongoing collaborative adaptation (National Institute on Drug Abuse [NIDA], 2023; SAMHSA, 2022a).

Government Entities: The Foundation of Effective Addiction Policy

Government bodies provide the legal, financial, and strategic architecture for addiction policy. The Ministry of Health (or equivalent) typically leads in formulating national addiction strategies, setting quality standards for treatment services, and regulating controlled substances. For instance, Health Canada spearheads Canada's national drug strategy, which includes prevention, treatment, harm reduction, and enforcement pillars, emphasizing a public health approach (Government of Canada, 2023). In the U.S., the Department of Health and Human Services (HHS) plays a similar role. A critical function is ensuring the availability of essential medicines for addiction treatment, such as methadone and buprenorphine. Challenges like drug shortages can impede these efforts, highlighting the need for stronger federal leadership and better data to prevent and mitigate shortages (U.S. Government Accountability Office [GAO], 2023).

Sustainable financing is paramount for effective addiction policy. National Health Funds or equivalent insurance systems must design payment models that incentivize evidence-based addiction treatment, including Medication for Opioid Use Disorder (MOUD) and psychosocial therapies. In Portugal, following decriminalization in 2001, the national health system absorbed the costs of addiction treatment. This policy shift, alongside expanded prevention and harm reduction efforts, contributed to a decrease in problematic drug use and a dramatic fall in new HIV diagnoses among people who inject drugs (Hughes & Stevens, 2010; Transform Drug Policy Foundation, 2021). The design of these mechanisms must ensure equitable access, preventing financial barriers from hindering treatment initiation or continuation.

Specialized drug prevention agencies provide crucial technical expertise, support data collection and analysis, and coordinate efforts across various governmental and non-governmental actors. For example, Paraguay's National Anti-Drug Secretariat (SENAD) coordinates national drug policy, including prevention and treatment efforts (Organization of American States [OAS], 2019). Such bureaus often lead prevention campaigns, develop training materials for professionals, and monitor emerging drug trends. Their coordination role is vital in linking health services with law enforcement and social services, as seen in cross-sector collaborations like the Law Enforcement Assisted Diversion (LEAD) programs found in various U.S. cities, which divert individuals with SUDs to community-based services instead of jail (LEAD National Support Bureau, 2021).

Professional Organizations: Upholding Standards and Building Capacity

Professional bodies are essential for upholding standards, disseminating best practices, and building workforce capacity in addiction treatment. Pharmaceutical associations play a key role in setting ethical and professional standards for pharmacists, who are increasingly recognized as crucial frontline providers in addiction care. They can advocate for policies that expand pharmacists' scope of practice, such as dispensing naloxone without a prescription or administering MOUD (American Pharmacists Association, 2022). Research supports the feasibility and acceptability of pharmacy-based harm reduction interventions, including providing addiction treatment information (Hales et al., 2019; CDC, 2024). In countries like Scotland, community pharmacies are integral to the National Naloxone Programme, significantly contributing to overdose prevention (Scottish Government, 2023).

Societies of addiction medicine are vital for developing evidence-based clinical guidelines, promoting research, and providing specialized training and certification for addiction professionals. They ensure that practitioners are equipped with the latest knowledge on treating SUDs, including the integration of harm reduction therapy with traditional approaches (Denning, 2001; Mee-Lee et al., 2013). For example, the American Society of Addiction Medicine (ASAM) develops widely used criteria for patient placement and treatment planning (ASAM, 2023).

Primary care physicians are often the first point of contact for individuals with SUDs. Associations representing them are crucial for developing clear referral pathways to specialized treatment and for integrating screening, brief intervention, and referral to treatment (SBIRT) into routine practice (Humeniuk et al., 2012). They can also champion the role of family physicians in providing MOUD, particularly in rural or underserved areas where specialists are scarce (American Academy of Family Physicians, 2023). The CURE project in England, a secondary care tobacco addiction treatment pathway, highlights the importance of understanding implementation strategies for such pathways (Naughton et al., 2022), which can inform primary care referral models for various SUDs.

Civil Society Partners: Bringing Grassroots Perspectives to Policy

Civil society organizations bring invaluable grassroots perspectives, direct service provision, and advocacy to addiction policy development. Patient advocacy organizations amplify the voices of individuals with lived and living experience (PWLLE) of addiction and their families. They advocate for patient-centered care, fight stigma, and ensure that policies and services are responsive to community needs (Faces & Voices of Recovery, 2022). Their meaningful involvement in co-designing services, policy development, and research can lead to higher engagement and better outcomes (Pijl et al., 2021). Models of meaningful involvement emphasize moving beyond tokenistic consultation to genuine partnership and shared leadership (International Network of People who Use Drugs, 2021).

Harm reduction NGOs are at the forefront of innovative service delivery, providing needle and syringe programs, naloxone distribution, overdose prevention education, and, where legal, supervised consumption services (Harm Reduction International, 2022). SAMHSA emphasizes harm reduction as a critical component of a comprehensive, integrated approach to substance use (SAMHSA, 2024a). Countries like Canada have seen significant public health benefits from NGO-led supervised consumption sites, reducing overdose deaths and transmission of blood-borne viruses (Kerr et al., 2007; Kennedy et al., 2017). These NGOs often reach populations that traditional services struggle to engage. While evidence supports the effectiveness of harm reduction, implementation can face challenges such as community resistance and securing sustainable funding (Strike et al., 2020).

Recovery community organizations (RCOs), often led by individuals in recovery, provide essential peer support services, recovery coaching, and help navigate social determinants of health like housing and employment (White & Mojer-Torres, 2010). Peer support is increasingly recognized as an evidence-based practice that improves engagement, reduces relapse rates, and enhances overall well-being (SAMHSA, 2017; Bassuk et al., 2016). Integrating RCOs into the formal treatment continuum strengthens long-term recovery capital. This includes faith-based recovery organizations, which play a significant role in many communities, offering spiritual support alongside practical assistance (Priester et al., 2008).

Academic Institutions: Ensuring Evidence-Informed Policies

Academic institutions contribute through research, education, and evaluation, ensuring that addiction policies are evidence-informed and effective. Pharmacy schools are critical in preparing future pharmacists to address addiction. This includes curriculum development on pain management, SUD screening, MOUD, naloxone dispensing, harm reduction principles, and the use of digital health tools in pharmacy practice (American Association of Colleges of Pharmacy, 2022). They also conduct research on pharmacy-based interventions to improve medication adherence and treatment outcomes (CDC, 2024; Sajatovic et al., 2009).

Public health institutes and university research centers conduct epidemiological surveillance, evaluate the effectiveness and cost-effectiveness of addiction policies and interventions, and monitor treatment outcomes (NIDA, 2022). This data is crucial for policy refinement and accountability. For example, the Canadian Institute for Substance Use Research (CISUR) provides national leadership in research to reduce alcohol- and other drug-related harm (CISUR, n.d.). The implementation of Electronic Health Record (EHR) integrated clinical pathways shows promise for improving adherence to guidelines in addiction care, and public health institutes can evaluate such implementations, including those involving telehealth and digital health platforms.

Collaboration with international researchers and institutions facilitates the transfer of knowledge, best practices, and innovative models. This allows for the adaptation of successful strategies to the local context, avoiding the duplication of efforts and accelerating policy development. Portugal's health-led decriminalization approach, focusing on treatment and social reintegration over criminal penalties for personal use, has been widely studied for its impacts on drug-related deaths, HIV transmission, and the burden on the criminal justice system (Hughes & Stevens, 2010; Transform Drug Policy Foundation, 2021). Switzerland's "four-pillar" policy includes long-standing harm reduction programs like heroin-assisted treatment (HAT) and supervised consumption sites, which have been associated with reduced mortality, improved health, and decreased crime among participants (Klingemann & Burkhart, 2003; Uchtenhagen, 2010).

Private Sector Stakeholders: Balancing Interests with Public Health Goals

The private sector plays a multifaceted role in addiction policy and its implementation, with interests that can both align with and diverge from public health goals. Pharmaceutical companies are central to the development, manufacturing, and distribution of medications for pain management, MOUD, and overdose reversal. Their role includes research and development of new therapies, but also involves responsibilities regarding ethical marketing, pricing, and ensuring access while preventing diversion (National Academies of Sciences, Engineering, and Medicine [NASEM], 2017). Collaboration is needed to ensure a stable supply of essential addiction medications and to develop innovative, less abusable pain treatments.

Public and private insurance providers significantly influence access to addiction treatment through coverage policies, reimbursement rates, prior authorization requirements, and network adequacy (McCollister et al., 2019). Collaborative efforts are needed to ensure that insurance policies align with evidence-based practices, promote parity for mental health and substance use disorder treatment, and reduce financial barriers to care (The Kennedy Forum, 2021).

Workplaces can be crucial sites for prevention, early intervention, and recovery support. Employers can implement Employee Assistance Programs (EAPs), promote health and wellness, adopt recovery-supportive workplace policies, and reduce stigma (SAMHSA, 2022c). Collaboration with employers can expand access to resources and support continued employment for individuals in recovery.

Technology and Digital Health: New Frontiers in Addiction Treatment

The rapid evolution of technology offers new avenues for addressing addiction, requiring collaboration with a new set of stakeholders. Companies developing mobile apps, online platforms, and wearable technologies for addiction prevention, treatment, and recovery support are increasingly prevalent (Marsch et al., 2020). Collaboration is needed to ensure these tools are evidence-based, protect user privacy, integrate with existing health systems, and are accessible to diverse populations.

Specialized telehealth companies and traditional providers offering remote addiction services have expanded significantly, especially post-COVID-19 (NIDA, 2023). Collaboration with regulatory bodies, payers, and professional organizations is essential to establish quality standards, ensure equitable access, and integrate telehealth into broader care continuums. Firms specializing in health data analytics can support MSCFs by helping to identify at-risk populations, track treatment outcomes, evaluate program effectiveness, and facilitate data sharing across sectors while adhering to privacy regulations (Belle et al., 2015).

Criminal Justice System: Bridging Public Health and Public Safety

Given the historical and ongoing intersection of substance use and the criminal justice system, collaboration with these stakeholders is critical. Drug treatment courts and other problem-solving courts aim to divert individuals with SUDs from incarceration into treatment programs, requiring close collaboration between judges, prosecutors, defense attorneys, treatment providers, and community services (National Association of Drug Court Professionals, 2022).

Jails and prisons house a large number of individuals with SUDs. Collaboration is needed to provide evidence-based treatment, including MOUD, within correctional settings and to ensure continuity of care upon re-entry into the community (NASEM, 2017). Community supervision officers play a key role in monitoring individuals with SUDs and connecting them to treatment and recovery resources. Effective collaboration with treatment providers is essential for successful outcomes (Taxman & Belenko, 2012).

Law enforcement agencies are increasingly involved in pre-arrest diversion programs that redirect individuals to treatment and social services instead of arrest and prosecution, requiring strong partnerships with health and community organizations (Bureau of Justice Assistance [BJA], n.d.; COSSUP, c. 2020). These initiatives represent a significant shift toward treating addiction as a public health issue rather than solely a criminal justice concern.

Culturally-Specific and Indigenous Approaches: Ensuring Equity and Relevance

Effective MSCFs must recognize and integrate culturally-specific approaches to addiction, particularly for Indigenous and minority communities who often face disparities in access and outcomes. For Indigenous populations, collaboration must respect sovereignty and incorporate traditional healing practices, cultural knowledge, and community-led initiatives. This includes partnering with tribal health services, elders, and traditional healers (Gone & Trimble, 2012).

Mainstream evidence-based practices may require adaptation to be effective in diverse cultural contexts. Collaboration with community leaders and members is essential to ensure interventions are culturally sensitive, relevant, and acceptable (Bernal & Domenech Rodríguez, 2012). Recognizing and valuing community-defined evidence, which emerges from the lived experiences and cultural wisdom of specific communities, is crucial for developing effective and trusted interventions (Subramony & Hayfron, 2021). This requires partnerships that empower communities to define their own needs and solutions.

Persistent Challenges in Addiction Policy Implementation

Despite the clear benefits of multi-stakeholder collaboration, several challenges persist in implementing effective addiction policies. Pervasive stigma against people who use drugs and those with SUDs hinders help-seeking, policy support for compassionate, evidence-based approaches, and the integration of people with lived experience in decision-making (WHO, 2017; Livingston et al., 2012).

Inadequate, often siloed, and inconsistently sustained funding for addiction prevention, treatment, harm reduction, and recovery support services remains a major barrier to comprehensive care (NASEM, 2016; Buck, 2011). Shortages of trained addiction specialists, including physicians, counselors, peer support workers, and culturally competent providers, limit service capacity and quality (SAMHSA, 2023b).

Fragmented data systems, lack of interoperability, and privacy concerns make comprehensive needs assessment, service coordination, and outcomes monitoring difficult (ASPE, 2015; Office of the National Coordinator for Health Information Technology, 2021). Conflicting policies across different government sectors can undermine effectiveness and create confusion (UNODC, 2023; Saloner et al., 2021).

Building and maintaining effective collaboration requires dedicated resources, clear roles, mutual trust, shared vision, and ongoing communication. Addressing inherent power imbalances and conflicting interests among diverse stakeholders is a significant and ongoing challenge (Bryson et al., 2006; Emerson et al., 2012). Addiction is deeply intertwined with social determinants like poverty, housing instability, unemployment, trauma, and discrimination. MSCFs must effectively engage sectors beyond healthcare to address these root causes (Compton & Volkow, 2006).

The emergence of new psychoactive substances, changing drug use patterns, and the rapid evolution of digital technologies require agile and adaptive collaborative responses (Ciccarone, 2021; NIDA, 2023). By systematically addressing these challenges and fostering robust, equitable, and adaptive multi-stakeholder collaboration, policymakers can create more effective, humane, and just addiction policies that improve public health and safety. This requires a commitment to shared leadership, particularly elevating the voices and expertise of people with lived and living experience (Pijl et al., 2021).

Monitoring and Evaluation Framework for Addiction Policies

A robust Monitoring and Evaluation (M&E) framework serves as the cornerstone for assessing the effectiveness, efficiency, equity, and impact of addiction policies, particularly those involving innovative service delivery models like pharmacy-based interventions. Such frameworks enable adaptive management, ensuring resources are directed toward strategies that demonstrably improve public health outcomes, advance health equity, and provide value for money. Globally, countries increasingly recognize the need for data-driven addiction policies. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, n.d.) emphasizes the importance of monitoring systems to inform drug policy development and evaluation across EU member states. Similarly, the United Nations Office on Drugs and Crime (UNODC, 2023) collects and disseminates global data on drug use and its consequences, highlighting the need for evidence-informed responses. The increasing prevalence of synthetic opioids, such as fentanyl and its analogues, and other emerging psychoactive substances, further underscores the need for agile and responsive M&E systems (Ciccarone, 2021; U.S. Drug Enforcement Administration, 2023).

Process Indicators: Measuring Implementation Fidelity

Process indicators are essential for understanding the extent to which a policy or program is being implemented as intended and reaching the target population. Pharmacists are increasingly recognized as accessible healthcare professionals who can play a vital role in addiction services, including harm reduction, screening, referral, and medication-assisted treatment (MAT) provision (Calvo et al., 2021; Ndefo et al., 2023). Specialized training is crucial to equip them with the necessary knowledge, skills, and confidence to address stigma. Recent legislative changes, such as the Mainstreaming Addiction Treatment (MAT) Act of 2023 in the US, which eliminated the federal X-waiver requirement for prescribing buprenorphine, create new opportunities for pharmacist involvement, making training even more critical (Consolidated Appropriations Act, 2023, Division FF, Section 1262). Evidence shows that even brief online training has demonstrated a positive impact on pharmacists' willingness to dispense buprenorphine (Freeman et al., 2023).

Ensuring equitable access to addiction services is paramount in policy implementation. Monitoring geographic distribution helps identify underserved areas, including rural, remote, and marginalized urban communities where access to specialized addiction treatment can be limited (Priester et al., 2016). This extends beyond geography to consider accessibility for diverse populations. Research indicates a community need for pharmacies to offer new services to reduce addiction and overdose (Calvo et al., 2021). The ECHO (Extension for Community Healthcare Outcomes) model has been used to extend addiction care expertise to rural areas, and a similar logic applies to leveraging pharmacies (Arora et al., 2011). Telehealth expansion, accelerated during the COVID-19 pandemic, offers a vital modality for increasing access, particularly for MAT and counseling, and its integration into pharmacy services should be monitored (SAMHSA, 2022).

Addiction is complex, often co-occurring with mental health conditions, and a comprehensive approach requires a suite of evidence-based services, including pharmacological and psychosocial interventions. Pharmacies can offer various harm reduction services (HHS, n.d.), and integration with primary care and mental health services is crucial. Pharmacist interventions have included medication take-back programs and other harm reduction strategies (Ghitza et al., 2020). The concept of Drug Utilization Review (DUR) is well-established and can be adapted to monitor and improve the safety of medications used in addiction treatment (AMCP, 2019). The importance of integrated care for co-occurring disorders is well-documented (Kelly & Fresetto, 2023).

Early identification and connection to care are crucial components of effective addiction policy. Pharmacies can serve as important screening and referral points, particularly for individuals not engaged with other health services (Calvo et al., 2021). The NIAAA highlights the importance of connecting patients to specialty treatment (NIAAA, n.d.). Resources like SAMHSA's FindTreatment.gov can be vital tools for referrals (SAMHSA, n.d.-a). A significant challenge in this area is ensuring "warm handoffs" where referrals lead to actual engagement with treatment services (Garnick et al., 2009). This requires strong collaboration and communication between pharmacies and treatment providers.

Outcome Indicators: Measuring Impact and Effectiveness

A successful pharmacy intervention system translates into individuals accessing and engaging with appropriate treatment. This is a key indicator of the pharmacy's role in the care cascade. Streamlining connections to care is critical (NIAAA, n.d.). The effectiveness of various treatments, such as contingency management for stimulant use disorder, underscores the importance of engaging patients (DeFulio et al., 2021). A significant challenge in this domain is tracking patients post-referral, which requires robust, privacy-protected data-sharing agreements and interoperable systems (SAMHSA, 2017).

Remaining in treatment for an adequate period is strongly correlated with better long-term outcomes, including reduced substance use, improved functioning, and enhanced recovery capital (NIDA, 2020). NIDA suggests that participation in treatment for less than 90 days is of limited effectiveness for many individuals, and longer durations are often recommended (NIDA, 2020, "How long does drug addiction treatment usually last?"). Portugal's health-led approach, following decriminalization, emphasized psychosocial support alongside treatment, contributing to improved engagement, though direct comparisons are complex (Transforming Drug Policy, 2018).

A primary goal of many addiction policies, especially those incorporating harm reduction, is to reduce mortality and morbidity associated with drug use. The CDC emphasizes comprehensive overdose prevention strategies (CDC, 2023a). Harm reduction services, including naloxone distribution and access to sterile syringes, are evidence-based strategies to minimize negative consequences (Dasgupta et al., 2023; HHS, n.d.). Australia's early adoption and scaling up of needle and syringe programs (NSPs) is credited with dramatically curbing HIV epidemics among people who inject drugs (Commonwealth of Australia, 2017a). Similarly, Portugal's comprehensive approach was followed by significant decreases in drug-related deaths and HIV infections among people who inject drugs (Hughes & Stevens, 2010).

Patient perspectives are crucial for evaluating service quality, accessibility, cultural appropriateness, and identifying barriers like stigma, which can deter help-seeking and engagement. The feasibility and acceptability of pharmacy-based harm reduction services are important considerations (Calvo et al., 2021). Reducing stigma is a key component of improving access and engagement in addiction treatment (NIDA, 2020, "How can we reduce the stigma of drug addiction?"). Collecting sensitive information requires trust, confidentiality, and culturally appropriate methods, often best achieved through anonymous surveys or qualitative interviews conducted by independent researchers or peer navigators.

Addiction policies can have broader impacts on the community beyond individual patient outcomes. Effective treatment and harm reduction can contribute to reduced crime and improved community well-being (NIDA, 2020). Monitoring these community-level outcomes provides a more comprehensive picture of policy impact.

Economic Indicators: Assessing Financial Viability and Value

Demonstrating cost-effectiveness is vital for securing ongoing funding and scaling up successful interventions in addiction policy. While comprehensive cost-effectiveness data for integrated pharmacy-based addiction services is still developing, individual components like naloxone provision have been shown to be highly cost-effective (Townsend et al., 2020). Economic evaluations of supervised consumption services in Canada have shown them to be cost-effective by preventing overdose deaths and reducing transmission of HIV and HCV (Andresen & Boyd, 2010; Bayoumi & Zaric, 2008).

Effective addiction treatment and harm reduction can reduce costly acute care episodes and improve overall health system efficiency. Studies on MAT and harm reduction services consistently show reductions in healthcare utilization and associated costs (NIDA, 2020, "Is drug addiction treatment worth its cost?"). For example, individuals engaged in MAT are less likely to require emergency medical services for overdose (Sederer et al., 2017). A challenge in this area is attributing changes in healthcare utilization solely to the pharmacy intervention due to confounding factors; rigorous quasi-experimental study designs are needed.

Policymakers need to understand the broader economic benefits of investing in addiction services, including savings in healthcare, criminal justice, and increased productivity. The societal costs of untreated addiction are immense. NIDA states that "Substance abuse costs our Nation over $600 billion annually and treatment can help reduce these costs. Drug addiction treatment has been shown to reduce associated health and social costs by far more than the cost of the treatment itself." (NIDA, 2020, "Is drug addiction treatment worth its cost?"). More specifically, studies have indicated that every dollar invested in addiction treatment programs can yield a return of between $4 and $7 in reduced drug-related crime, criminal justice costs, and theft (NIDA, 2020, citing various studies). When savings related to healthcare are included, total savings can exceed costs by a ratio of 12 to 1 (NIDA, 2020, citing various studies).

For pharmacy-based models to be sustainable, they must be financially and operationally viable for the participating pharmacies, and the impact on the pharmacy workforce must be manageable. The feasibility of new pharmacy services often hinges on adequate reimbursement and integration into existing workflows (Calvo et al., 2021). Without this, widespread adoption is unlikely. Current reimbursement models in many jurisdictions may not adequately compensate pharmacists for the time, expertise, and additional responsibilities required to deliver comprehensive addiction services, posing a barrier to sustainability and potentially leading to workforce burnout (McCann et al., 2018; Schindel et al., 2021).

Equity Considerations in Addiction Policy Evaluation

It is crucial to ensure that addiction policies and interventions reduce, rather than exacerbate, health disparities. M&E must actively monitor equity. All process, outcome, and economic indicators should be stratified by key demographic variables (e.g., race, ethnicity, socioeconomic status, gender identity, sexual orientation, geographic location, disability status) to identify disparities in access, service uptake, and outcomes. Evaluating the effectiveness of strategies to reach and engage marginalized populations is essential, as is assessing the cultural appropriateness and safety of services for diverse groups. Monitoring and evaluating efforts to mitigate structural barriers such as housing instability, lack of transportation, childcare needs, and involvement with the criminal justice system that disproportionately affect certain populations and hinder access to and success in treatment is also critical (Office of Disease Prevention and Health Promotion, n.d.).

Ethical Considerations in Data Collection and Analysis

The collection, storage, analysis, and reporting of data related to addiction carry significant ethical responsibilities, particularly concerning privacy, confidentiality, and potential for stigmatization. Ensuring robust informed consent processes for data collection from individuals, clearly explaining how data will be used, stored, and protected is essential. Implementing stringent data security measures compliant with regulations like HIPAA in the US or GDPR in Europe, and 42 CFR Part 2 for substance use disorder treatment information in the US (SAMHSA, 2017) is necessary. Protecting the identities of individuals and participating pharmacies, especially in smaller communities where anonymity may be harder to maintain, collecting only the data necessary for M&E purposes, ensuring that data reporting does not inadvertently stigmatize individuals or communities, and involving community members, including people with lived and living experience, in the design and oversight of M&E activities are all crucial ethical considerations.

Research Partnerships and Methodological Approaches

Collaborations with academic institutions, research organizations, and community partners (including people with lived experience) are invaluable for conducting rigorous, ethical, and relevant evaluations. Combining quantitative data with qualitative data provides a more comprehensive understanding of program implementation, impact, context, and unintended consequences. Mixed-methods evaluations are increasingly used to assess complex health interventions, including addiction services (Creswell & Clark, 2017).

When feasible, designs like interrupted time series analyses (ITSA), comparative cohort studies, or stepped-wedge cluster randomized trials can provide stronger evidence of causality. ITSA can assess changes in overdose rates or treatment initiation following policy implementation. Comparative studies can compare outcomes in areas with and without the intervention.

Implementation science frameworks (e.g., RE-AIM, CFIR) help assess the reach, effectiveness, adoption, implementation, and maintenance of interventions, and identify factors influencing successful scale-up and sustainability (Damschroder et al., 2009). These frameworks can be used to evaluate how well pharmacy-based services are adopted by different types of pharmacies and how implementation fidelity is maintained over time.

Economic evaluations are essential to demonstrate value for money and inform resource allocation decisions. Cost-effectiveness analyses (comparing costs to health outcomes like QALYs gained or overdoses averted), cost-benefit analyses (monetizing all costs and benefits), and budget impact analyses should be utilized, along with systematic reviews and meta-analyses of economic evaluations where available.

The rapid expansion of digital health tools and telehealth for addiction services requires specific M&E approaches. Metrics on uptake of telehealth services, patient and provider satisfaction with virtual care, impact on access for remote or underserved populations, and clinical outcomes achieved via telehealth compared to in-person services should be included (Lin et al., 2022).

Current Challenges in Addiction Policy Implementation and Evaluation

Several significant challenges exist in implementing and evaluating addiction policies. Health data, social service data, and criminal justice data often reside in separate, non-interoperable systems, making comprehensive M&E and tracking of individuals across systems extremely difficult (SAMHSA, 2017; Vest & Gamm, 2010). Pervasive stigma surrounding substance use and mental health can deter individuals from seeking help, affect disclosure in data collection, and influence policy support and funding for M&E (Livingston et al., 2012; NIDA, 2020). M&E activities require dedicated, sustained funding, which can be challenging to secure and maintain, especially for long-term outcome tracking and evaluation of policy coherence across different government departments.

Shortages of trained personnel in addiction treatment (including those skilled in psychosocial interventions and culturally competent care), harm reduction, and M&E can hinder effective implementation and evaluation (SAMHSA, 2021). The rapid emergence of new psychoactive substances (e.g., novel synthetic opioids, xylazine) and changing patterns of polysubstance use require agile M&E systems that can quickly detect and respond to new trends (Ciccarone, 2021; Friedman et al., 2022).

Addiction is often addressed through multiple government departments and levels of government, which can lead to fragmented policies and difficulties in coordinated M&E. Effectively measuring and addressing how social determinants of health (e.g., housing, employment, education, discrimination) and structural barriers impact addiction and recovery outcomes requires complex, multi-sectoral M&E approaches (Compton & Shim, 2015).

M&E frameworks need to be flexible enough to evaluate programs with different philosophical underpinnings, recognizing a spectrum of recovery goals and outcomes. This can create tension in selecting appropriate indicators. Pharmacy-based interventions, while promising, may have unintended negative consequences (e.g., increased pharmacist burden, privacy concerns in small communities, potential for diversion if not managed well) that need to be monitored (Langford et al., 2022).

By systematically collecting and analyzing data across process, outcome, economic, equity, and ethical dimensions, and by fostering strong, inclusive research partnerships, policymakers can build a learning system that continuously improves the effectiveness, equity, and reach of addiction policies. This includes integrating psychosocial interventions effectively alongside pharmacological approaches and ensuring that diverse stakeholder perspectives, especially those of individuals with lived and living experience, inform all stages of the M&E process.

Conclusion

The Pharmacist-Initiated Addiction Support Network proposed in this paper represents a transformative approach to addressing Poland's significant challenges in addiction treatment access and delivery. By leveraging the country's extensive pharmacy network, this model offers a practical solution to bridge the substantial treatment gap that currently leaves 70-85% of individuals with substance use disorders without specialized care.

The international evidence reviewed demonstrates that pharmacists can effectively deliver a range of addiction services, from screening and brief interventions to harm reduction and medication management. Countries like Scotland, Canada, and Australia have successfully integrated pharmacists into their addiction care systems, achieving improved access, reduced stigma, and better health outcomes. These models provide valuable lessons while highlighting the need for adaptation to Poland's unique healthcare structure, cultural context, and specific substance use patterns.

Implementation of this vision requires a carefully orchestrated approach that addresses several interconnected domains:

First, regulatory reforms must expand pharmacists' scope of practice to include addiction screening, naloxone provision without prescription, supervised consumption services, and other evidence-based interventions. These changes should be accompanied by privacy requirements for consultation spaces and consideration of broader drug policy reforms to reduce stigma and barriers to help-seeking.

Second, sustainable financing mechanisms through the National Health Fund must be established, including billing codes for addiction services, reimbursement for harm reduction supplies, and financial incentives for pharmacies serving high-need communities. These investments should be justified through rigorous economic evaluation demonstrating long-term cost savings.

Third, comprehensive professional development programs must equip pharmacists with the knowledge, skills, and confidence to address addiction effectively and compassionately. This includes specialized education in pharmacy curricula, continuing education for practicing pharmacists, mentorship programs, and certification pathways.

Fourth, a robust multi-stakeholder collaboration framework must bring together government entities, professional organizations, civil society partners, academic institutions, and the private sector. This collaboration should elevate the voices of people with lived experience and ensure coordination across health, social service, and criminal justice systems.

Finally, a comprehensive monitoring and evaluation framework must track implementation fidelity, health outcomes, economic impact, and equity considerations to guide continuous improvement and demonstrate effectiveness.

The challenges in implementing this vision are substantial, including potential resistance from other healthcare professionals, stigma surrounding addiction, workforce capacity concerns, and the need for significant policy and financial commitments. However, the potential benefits far outweigh these challenges. By creating a more accessible, comprehensive, and integrated addiction care system, Poland can significantly reduce substance-related harm, improve public health outcomes, decrease healthcare costs, and offer more humane and effective support to individuals struggling with addiction.

As Poland continues to evolve its healthcare system, this pharmacist-initiated model represents a forward-thinking approach that aligns with global best practices while addressing local needs. With strong political will, sustained funding, and collaborative implementation, this vision can transform addiction care in Poland and serve as a model for other countries facing similar challenges in ensuring equitable access to evidence-based addiction services.

References

Academy of Managed Care Pharmacy. (2019). Drug utilization review. AMCP.

Alberta College of Pharmacy. (2023). Standards of practice for pharmacists and pharmacy technicians.

American Academy of Family Physicians. (2023). [No title provided]

American Addiction Centers. (2024). Medication-assisted treatment (MAT). https://americanaddictioncenters.org/addiction-medications

American Association of Colleges of Pharmacy. (2022). [No title provided]

American Pharmacists Association & National Association of Chain Drug Stores Foundation. (2008). Medication therapy management in pharmacy practice: Core elements of an MTM service model (version 2.0). Journal of the American Pharmacists Association, 48(3), 341-353.

American Pharmacists Association. (2022). [No title provided]

American Society of Addiction Medicine (ASAM). (2023). [No title provided]

American Society of Addiction Medicine (ASAM). (n.d.). Retrieved from https://www.asam.org/

Amundstuen, G. R., Høiseth, G., Skurtveit, S., Bramness, J. G., & Clausen, T. (2021). Dispensing of benzodiazepines and benzodiazepine-related drugs to pregnant women: A population-based cohort study. European Journal of Clinical Pharmacology, 77(2), 247-257.

Andresen, M. A., & Boyd, N. (2010). A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. International Journal of Drug Policy, 21(1), 70-76.

Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., Parish, B., Burke, T., Pak, W., Dunkelberg, J., Kistin, M., Brown, J., Jenkusky, S., Komaromy, M., & Qualls, C. (2011). Outcomes of treatment for hepatitis C virus infection by primary care providers. New England Journal of Medicine, 364(23), 2199-2207.

ASPE. (2015). [No title provided]

ATTC Network. (2024). Pharmacist training in addiction medicine.

Australian Government Department of Health and Aged Care. (2017). National Drug Strategy 2017–2026.

Australian Government Department of Health and Aged Care. (2023). Needle and syringe programs. https://www.health.gov.au/health-topics/drugs/about-drugs/needle-and-syringe-programs

Australian Government Department of Health and Aged Care. (2023). Opioid Dependence Treatment (ODT) Program.

Australian Injecting & Illicit Drug Users League. (2021). Community engagement strategies for harm reduction services.

Australian Institute of Health and Welfare. (2022b). Rural and remote health.

Australian Journal of Rural Health. (2021). Evaluation of rural pharmacy initiatives.

Australian Primary Health Care Nurses Association. (2020). Screening and brief intervention techniques.

Babor, T. F., McRee, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. (2007). Screening, Brief Intervention, and Referral to Treatment (SBIRT): Toward a public health approach to the management of substance abuse. Substance Abuse, 28(3), 7-30.

Bach, P., & Goad, J. (2015). The role of community pharmacy-based vaccination in the USA: Current practice and future directions. Integrated Pharmacy Research and Practice, 4, 67-77.

Bassuk, E. L., Hanson, J., Greene, R. N., Richard, M., & Laudet, A. (2016). [No title provided]

Bauer, M. S., Damschroder, L., Hagedorn, H., Smith, J., & Kilbourne, A. M. (2015). An introduction to implementation science for the non-specialist. BMC Psychology, 3(1), 32.

Bauld, L., Bell, K., McCullough, L., Richardson, L., & Greaves, L. (2011). The effectiveness of NHS smoking cessation services: A systematic review. Journal of Public Health, 32(1), 71-82.

Bayoumi, A. M., & Zaric, G. S. (2008). The cost-effectiveness of Vancouver's supervised injection facility. Canadian Medical Association Journal, 179(11), 1143-1151.

Bell, J., Strang, J., Marsden, J., Metrebian, N., Eastwood, B., Felton, A., & Keaney, F. (2016). Supervised injectable heroin and injectable methadone for the treatment of opiate dependence. British Journal of Psychiatry, 209(6), 481-486.

Belle, A., Thiagarajan, R., Soroushmehr, S. M., Navidi, F., Beard, D. A., & Najarian, K. (2015). [No title provided]

Bernal, G., & Domenech Rodríguez, M. M. (2012). [No title provided]

Boston Medical Center. (n.d.). Grayken Center for Addiction Training and Technical Assistance. Retrieved from https://www.bmc.org/addiction/training-education

Brothers, T. D., Leaman, M., Bonn, M., Lewer, D., Atkinson, J., Fraser, J., Gillis, A., Gniewek, M., Hawker, L., Hayman, H., Jorna, P., Martell, D., O'Donnell, T., Rivers-Bowerman, H., & Genge, L. (2022). Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug and Alcohol Dependence, 235, 109440.

Bryson, J. M., Crosby, B. C., & Stone, M. M. (2006). [No title provided]

Buck, J. A. (2011). [No title provided]

Bureau of Justice Assistance (BJA). (n.d.). [No title provided]

Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Archives of Internal Medicine, 158(16), 1789-1795.

California State Board of Pharmacy. (2023). Pharmacists Recovery Program.

Calvo, M., MacFarlane, J., Zaccaro, H., Curtis, M., Cabán, M., Favaro, J., Passannante, M., & Frost, T. (2021). The use of naloxone in New Jersey pharmacies: A qualitative study. Journal of the American Pharmacists Association, 61(4), 429-435.

Canadian Agency for Drugs and Technologies in Health. (2021). Naloxone distribution strategies.

Canadian Centre on Substance Use and Addiction. (2022). Patient perspectives on pharmacy-based addiction services.

Canadian Institute for Substance Use Research (CISUR). (n.d.). [No title provided]

Canadian Medical Association Journal. (2023). Prescribed safer supply: Ongoing evaluation.

Canadian Pharmacists Association. (2021). Retrieved from https://www.pharmacists.ca/

Canadian Pharmacists Association. (2022). Scope of practice.

Canadian Pharmacists Association. (2023). Opioid crisis in Canada.

Carrieri, M. P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & Woody, G. E. (2000). Buprenorphine use: The international experience. Clinical Infectious Diseases, 43(Supplement_4), S197-S215.

CBOS. (2019). Retrieved from https://www.cbos.pl/

CDC. (2024). Medication-assisted treatment for opioid use disorder.

Centers for Disease Control and Prevention (CDC). (2024). [No title provided]

Centers for Disease Control and Prevention (CDC). (2024). Substance use disorder treatment. Retrieved from https://www.cdc.gov/

Centers for Disease Control and Prevention. (2023a). Overdose prevention. CDC.

Ciccarone, D. (2021). [No title provided]

Ciccarone, D. (2021). The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Current Opinion in Psychiatry, 34(4), 344-350.

College of Pharmacists of British Columbia. (2017). Professional practice policy – 66: Opioid agonist treatment. https://library.bcpharmacists.org/6_Resources/6-2_PPP/PPP66_Policy_Guide_OAT.pdf

College of Pharmacists of British Columbia. (2023). Opioid Agonist Treatment.

College of Pharmacists of British Columbia. (2023). Professional practice policies.

Commonwealth of Australia. (2017a). National drug strategy 2017-2026. Department of Health.

Community Pharmacy Scotland. (2023). Pharmacy service remuneration.

Compton, M. T., & Shim, R. S. (2015). The social determinants of mental health. Focus, 13(4), 419-425.

Compton, W. M., & Volkow, N. D. (2006). [No title provided]

Consolidated Appropriations Act, 2023, Division FF, Section 1262. (2023).

Copello, A., Templeton, L., & Powell, J. (2009). Adult family members and carers of dependent drug users: Prevalence, social cost, resource savings and treatment responses. UK Drug Policy Commission, 50(12), 45-52.

COSSUP. (c. 2020). [No title provided]

CRANAplus. (2022). Rural and remote health practice.

Crapanzano, K., Hammarlund, R., Ahmad, B., Hunsinger, N., & Kullar, R. (2019). The association between perceived stigma and substance use disorder treatment outcomes: A review. Substance Abuse and Rehabilitation, 10, 1-12.

Creswell, J. W., & Clark, V. L. P. (2017). Designing and conducting mixed methods research (3rd ed.). SAGE Publications.

Damschroder, L. J., Aron, D. C., Keith, R. E., Kirsh, S. R., Alexander, J. A., & Lowery, J. C. (2009). Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implementation Science, 4(1), 50.

Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2021). Opioid addiction: The current scenario in India. Indian Journal of Psychiatry, 63(1), 59-64.

Dasgupta, N., Figgatt, M. C., Krawczyk, N., Silver, R., & Rigg, K. K. (2023). Stigma and the etiology of addiction. The New England Journal of Medicine, 388(7), 599-602.

DEA. (n.d.). Drug disposal information. U.S. Drug Enforcement Administration. https://www.dea.gov/drug-disposal-information

Deeble Institute for Health Policy Research. (2020). Cost-effectiveness of rural health interventions.

DeFulio, A., Rzeszutek, M. J., Furgeson, J., Ryan, S., & Rezania, S. (2021). A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program. Journal of Substance Abuse Treatment, 120, 108188.

Denning, P. (2001). [No title provided]

Dhital, R., Norman, I., Whittlesea, C., Murrells, T., & McCambridge, J. (2010). The effectiveness of brief alcohol interventions delivered by community pharmacists: Randomized controlled trial. Addiction, 110(10), 1586-1594.

Drug Misuse and Dependence UK. (2020). Clinical guidelines on drug misuse and dependence.

EMCDDA. (2023a). Poland country drug report 2023.

EMCDDA. (2023a). Poland country drug report 2023. European Monitoring Centre for Drugs and Drug Addiction.

EMCDDA. (2023b). European drug report 2023: Trends and developments. European Monitoring Centre for Drugs and Drug Addiction.

Emerson, K., Nabatchi, T., & Balogh, S. (2012). [No title provided]

European Monitoring Centre for Drugs and Drug Addiction. (2022). Impact of COVID-19 on drug services and help-seeking in Europe.

European Monitoring Centre for Drugs and Drug Addiction. (2023). European Drug Report 2023: Trends and Developments.

European Monitoring Centre for Drugs and Drug Addiction. (2023a). European drug report 2023: Trends and developments. Publications Office of the European Union.

European Monitoring Centre for Drugs and Drug Addiction. (2023b). Poland country drug report 2023. Publications Office of the European Union.

European Monitoring Centre for Drugs and Drug Addiction. (n.d.). About us. EMCDDA.

Faces & Voices of Recovery. (2022). [No title provided]

Fixsen, D. L., Naoom, S. F., Blase, K. A., Friedman, R. M., & Wallace, F. (2005). Implementation research: A synthesis of the literature. University of South Florida, Louis de la Parte Florida Mental Health Institute, The National Implementation Research Network.

Freeman, P. R., Goodin, A., Troske, S., & Talbert, J. (2023). Impact of an educational intervention on pharmacists' attitudes toward dispensing buprenorphine and naloxone. Journal of the American Pharmacists Association, 63(1), 212-219.

Friedman, J., Akre, S., & Hengartner, M. P. (2022). Trends in benzodiazepine prescribing by age and sex in a commercially insured population in the United States, 2008-18. JAMA Network Open, 5(2), e2146156.

Gaciong, Z., & Grodzicki, T. (2020). The healthcare system in Poland. The Lancet, 396(10246), 237-238.

Galbraith, & Pharmaceutical Journal. (2022). Pharmacist burnout in addiction services.

Garnick, D. W., Lee, M. T., Horgan, C. M., & Acevedo, A. (2009). Adapting Washington Circle performance measures for public sector substance abuse treatment systems. Journal of Substance Abuse Treatment, 36(3), 265-277.

Gawron, A., Zagórska, A., & Piecuch, A. (2020). Pharmaceutical reimbursement in Poland. In Pharmaceutical reimbursement (pp. 1-20). Springer.

Gedeon, C., Sandell, M., Birkemose, I., Kakko, J., Runarsdottir, V., Simojoki, K., Clausen, T., Nyberg, F., Littlewood, R., & Alho, H. (2018). Standards for opioid use disorder care: An assessment of Nordic approaches. Nordic Studies on Alcohol and Drugs, 36(3), 286-298.

Ghitza, U. E., Tai, B., & Blanco, C. (2020). Pharmacist-delivered harm reduction services for people who use opioids: A call for action. Journal of the American Pharmacists Association, 60(6), 788-790.

Glabinski, L., Mravčík, V., Zabransky, T., Sárosi, P., & Malczewski, A. (2017). Harm reduction in Central and Eastern Europe. In T. Kolind, B. Thom, & G. Hunt (Eds.), The SAGE handbook of drug and alcohol studies (pp. 650-669). SAGE Publications.

Główny Inspektorat Farmaceutyczny. (2023). Retrieved from https://www.gov.pl/web/gif

Gmel, G., Heeb, J. L., & Rehm, J. (2001). Is frequency of drinking an indicator of problem drinking? A psychometric analysis of a modified version of the alcohol use disorders identification test in Switzerland. Drug and Alcohol Dependence, 64(2), 151-163.

Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W. (2018). Addressing the opioid crisis: A systematic review of the barriers and facilitators to opioid agonist treatment. International Journal of Drug Policy, 66, 69-79.

Gomes, T., Kitchen, S. A., & Tailor, L. (2021). Prescribing trends in Canada.

Gone, J. P., & Trimble, J. E. (2012). [No title provided]

Government of British Columbia. (2023). Prescribed safer supply.

Government of Canada. (2023). [No title provided]

Green, L. W., Ottoson, J. M., García, C., & Hiatt, R. A. (2015). Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annual Review of Public Health, 30, 151-174.

Gryczynski, J., Schwartz, R. P., Mitchell, S. G., O'Grady, K. E., & Ondersma, S. J. (2018). Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use. Drug and Alcohol Dependence, 193, 117-123.

Hales, J., Kiang, M. V., Zang, X., Bouton, T. C., Crockett, N., Lew, K. D., Stein, M. D., & Krieger, M. S. (2019). [No title provided]

Harm Reduction International. (2022). [No title provided]

Harm Reduction International. (n.d.). What is harm reduction? https://www.hri.global/what-is-harm-reduction

Harm Reduction Journal. (2023). Co-designing addiction services with people with lived experience.

Health Canada. (2022). Naloxone.

Horvat, N., Kos, M., & Košnik, M. (2020). Medication review and cognitive services provided by clinical pharmacists in Slovenia. Zdravstveni Vestnik, 89(11-12), 606-615.

Hughes, C. E., & Stevens, A. (2010). [No title provided]

Hughes, C. E., & Stevens, A. (2010). What can we learn from the Portuguese decriminalization of illicit drugs? British Journal of Criminology, 50(6), 999-1022.

Humeniuk, R., Henry-Edwards, S., Ali, R., Poznyak, V., & Monteiro, M. G. (2012). [No title provided]

International Journal of Drug Policy. (2022). Challenges in expanding harm reduction in South Africa.

International Network of People who Use Drugs. (2021). [No title provided]

International Pharmaceutical Federation. (2021). Pharmacy education in addiction medicine.

International Pharmaceutical Federation. (2022). Regulatory frameworks for pharmacy practice.

Jakubczyk, A., Michalska, A., Szejko, N., & Wojnar, M. (2013). Cost of alcohol dependence from the social perspective in Poland. Alcoholism and Drug Addiction, 26(4), 351-364.

Jasińska-Stroschein, M., Kurczewska, U., & Orszulak-Michalak, D. (2022). Pharmaceutical care in Poland: Challenges and opportunities. Pharmacy, 10(2), 45.

Jones, W., Elliott, L., & Seaton, R. A. (2019). The impact of pharmacy-based naloxone distribution programs. Canadian Pharmacists Journal, 152(2), 109-117.

Journal of Bioethical Inquiry. (2020). Ethical considerations in pharmacy-based addiction treatment.

Journal of Ethics in Mental Health. (2019). Ethical considerations in prescribing controlled substances.

Journal of Medical Internet Research. (2023). Digital health applications in addiction treatment.

Journal of Substance Abuse Treatment. (2021). Patient perspectives on pharmacy-based addiction services in South Africa.

KBPN. (2023). Annual report on the state of drug problems in Poland.

Kelly, T. M., & Fresetto, D. E. (2023). Integrated treatment of substance use and psychiatric disorders. Psychiatric Clinics of North America, 46(1), 1-17.

Kennedy, M. C., Karamouzian, M., & Kerr, T. (2017). [No title provided]

Kennie-Kaulbach, N., Farrell, B., Ward, N., Johnston, S., Gubbels, A., Eguale, T., Dolovich, L., Jorgenson, D., Waite, N., & Winslade, N. (2017). Pharmacist provision of primary health care: A modified Delphi validation of pharmacists' competencies. BMC Family Practice, 13, 27.

Kerr, T., Tyndall, M. W., Lai, C., Montaner, J. S., & Wood, E. (2007). [No title provided]

Klingemann, H., & Burkhart, G. (2003). [No title provided]

Kòmínda, K., Krysiński, J., Dymek, J., & Polak, S. (2020). Pharmacists' roles in addiction services: A systematic review. Journal of Pharmaceutical Policy and Practice, 13, 1-12.

Kowalski, M., & Nowak, P. (2022). Pharmaceutical care in Poland: Current situation and perspectives. Journal of Pharmaceutical Policy and Practice, 15(1), 1-10.

Krieger, M. S., Yedinak, J. L., Buxton, J. A., Lysyshyn, M., Bernstein, E., Rich, J. D., Green, T. C., Hadland, S. E., & Marshall, B. D. L. (2018). High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduction Journal, 15(1), 7.

Langford, R., Waldron, K. A., & Haskins, B. (2022). Pharmacist perceptions of barriers to providing naloxone in a community pharmacy setting. Journal of the American Pharmacists Association, 62(1), 208-213.

LDI Penn. (2019). Expanding access to naloxone: A review of distribution strategies.

LEAD National Support Bureau. (2021). [No title provided]

Leece, P., Khorasheh, T., Paul, N., Keller-Olaman, S., Massarella, S., Caldwell, J., Parkinson, M., Strike, C., Toner, L., Mamdani, M., & Gomes, T. (2020). 'Communities are attempting to tackle the crisis': A scoping review on community plans to prevent and reduce opioid-related harms. BMJ Open, 10(7), e035177.

Lin, L. A., Casteel, D., Shigekawa, E., Weyrich, M. S., Roby, D. H., & McMenamin, S. B. (2022). Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. Journal of Substance Abuse Treatment, 101, 108219.

Lisiecki, P., Marciniak, D., & Szpringer, M. (2021). Attitudes of patients towards pharmaceutical care in Poland. International Journal of Environmental Research and Public Health, 18(11), 5987.

Livingston, J. D., Milne, T., Fang, M. L., & Amari, E. (2012). [No title provided]

Livingston, J. D., Milne, T., Fang, M. L., & Amari, E. (2012). The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. Addiction, 107(1), 39-50.

Luty, J. (2003). What works in drug addiction? Advances in Psychiatric Treatment, 9(4), 280-288.

MacArthur, G. J., van Velzen, E., Palmateer, N., Kimber, J., Pharris, A., Hope, V., Taylor, A., Roy, K., Aspinall, E., Goldberg, D., Rhodes, T., Hedrich, D., Salminen, M., Hickman, M., & Hutchinson, S. J. (2015). Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. International Journal of Drug Policy, 25(1), 34-52.

Marsch, L. A., Guarino, H., Acosta, M., Aponte-Melendez, Y., Cleland, C., Grabinski, M., Brady, R., & Edwards, J. (2020). [No title provided]

Marsden, J., Darke, S., Hall, W., Hickman, M., Holmes, J., Humphreys, K., Neale, J., Tucker, J., & West, R. (2020). Mitigating and learning from the impact of COVID-19 infection on addictive disorders. Addiction, 115(6), 1007-1010.

Matheson, C., Bond, C. M., & Tinelli, M. (2011). Community pharmacy harm reduction services for drug misusers: National service delivery and professional attitude development over a decade in Scotland. Journal of Public Health, 33(2), 247-254.

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD002207.

McCann, L., Adair, C. G., & Hughes, C. M. (2018). An exploration of work-related stress in Northern Ireland community pharmacy: A qualitative study. International Journal of Pharmacy Practice, 26(2), 191-199.

McCollister, K. E., French, M. T., & Freitas, D. M. (2019). [No title provided]

Mee-Lee, D., Shulman, G. D., Fishman, M. J., Gastfriend, D. R., & Miller, M. M. (2013). [No title provided]

Merks, P., Religioni, U., Bilmin, K., Lewicki, J., Jakubowska, M., Waksmundzka-Walczuk, A., & Świeczkowski, D. (2021). Implementing patient pharmaceutical care in Poland. International Journal of Environmental Research and Public Health, 18(9), 4333.

Ministerstwo Zdrowia. (2023). Retrieved from https://www.gov.pl/web/zdrowie

Mravčík, V., Janíková, B., Drbohlavová, B., Popov, P., & Pirona, A. (2017). The complex relation between access to opioid agonist therapy and diversion of opioid medications: A case example of large-scale misuse of buprenorphine in the Czech Republic. Harm Reduction Journal, 14(1), 42.

Naczelna Izba Aptekarska [NIA]. (2022). Pharmaceutical care in Poland: Current status and perspectives.

Naczelna Izba Aptekarska [NIA]. (2023). Pharmacy statistics in Poland.

Naczelna Izba Aptekarska. (2022). Retrieved from https://www.nia.org.pl/

Naczelna Izba Aptekarska. (2023). Retrieved from https://www.nia.org.pl/

National Academies of Sciences, Engineering, and Medicine (NASEM). (2016). [No title provided]

National Academies of Sciences, Engineering, and Medicine (NASEM). (2017). [No title provided]

National Association of Drug Court Professionals. (2022). [No title provided]

National Health Fund (NFZ). (2023a). Financial plan for healthcare services. Retrieved from https://www.nfz.gov.pl/

National Health Fund (NFZ). (2023b). Retrieved from https://www.nfz.gov.pl/

National Institute on Alcohol Abuse and Alcoholism. (2022). Alcohol use disorder: A comparison of treatment options.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Treatment for alcohol problems: Finding and getting help. NIAAA.

National Institute on Drug Abuse (NIDA). (2022). [No title provided]

National Institute on Drug Abuse (NIDA). (2022). Harm reduction. Retrieved from https://nida.nih.gov/

National Institute on Drug Abuse (NIDA). (2023). [No title provided]

National Institute on Drug Abuse. (2020). Common comorbidities with substance use disorders research report. https://nida.nih.gov/publications/research-reports/common-comorbidities-substance-use-disorders/introduction

National Institute on Drug Abuse. (2020). Principles of drug addiction treatment: A research-based guide (3rd ed.). NIDA.

National Institute on Drug Abuse. (2022). Naloxone DrugFacts.

National Institute on Drug Abuse. (2023a). Screening and assessment tools chart. https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools

National Institute on Drug Abuse. (2023b). Misuse of prescription drugs research report. https://nida.nih.gov/publications/research-

National Institute on Drug Abuse. (n.d.). Mission and vision. https://nida.nih.gov/about-nida/mission-vision

National Rural Health Alliance. (2023). Rural pharmacy workforce challenges.

Naughton, F., Hopewell, S., Sinclair, L., McCaughan, D., McKell, J., Bauld, L., McEwen, A., & Begh, R. (2022). [No title provided]

Ndefo, U. A., Egede, B., & Rowland, K. (2023). Expanding the role of pharmacists in addressing the opioid crisis. American Journal of Health-System Pharmacy, 80(7), 645-651.

NHS Digital Services. (2023). Electronic health records and interoperability.

NHS Education for Scotland. (2022). Addiction medicine training for pharmacists.

NHS England. (2022). Community pharmacy. Retrieved from https://www.england.nhs.uk/

NIDA. (2023). Medications to treat opioid use disorder research report.

NJ Human Services. (2023). Naloxone distribution program.

Nosyk, B., Zang, X., Min, J. E., Krebs, E., Lima, V. D., Milloy, M. J., Kerr, T., Montaner, J. S., & Wood, E. (2016). Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: A modelling study. The Lancet HIV, 3(5), e242-e251.

NPR. (2018). Why is the opioid epidemic overwhelmingly white?

Office of Disease Prevention and Health Promotion. (n.d.). Social determinants of health. Healthy People 2030.

Office of the National Coordinator for Health Information Technology. (2021). [No title provided]

OKO.press. (2021). Retrieved from https://oko.press/

Okulicz-Kozaryn, K., & Marmot, M. (2018). Social and health-related determinants of alcohol consumption in Poland. Central European Journal of Public Health, 26(1), 47-52.

Olsen, A., McDonald, D., Lenton, S., & Dietze, P. M. (2020). Assessing the sustainability, scaling potential, and transferability of an intervention: The take-home naloxone program in Australia. Drug and Alcohol Review, 39(5), 590-599.

Ontario College of Pharmacists. (2022). Opioid policy.

Organization of American States (OAS). (2019). [No title provided]

Pan African Medical Journal. (2020). Pharmacist roles in HIV and substance use disorder management.

Parkes, T., Matheson, C., Carver, H., Budd, J., Liddell, D., Wallace, J., Pauly, B., Fotopoulou, M., Burley, A., Anderson, I., MacLennan, G., & Foster, R. (2019). Supporting harm reduction through peer support (SHARPS): Testing the feasibility and acceptability of a peer-delivered, relational intervention for people with problem substance use who are homeless, to improve health outcomes, quality of life and social functioning and reduce harms: Study protocol. Pilot and Feasibility Studies, 5, 64.

PARPA. (2022). State Agency for the Prevention of Alcohol-Related Problems. Retrieved from https://www.parpa.pl/

Persaud, N. (2020). Addressing the harms of prescription drug diversion.

Pharmaceutical Group of the European Union. (2021). Remuneration models for pharmacy services.

Pharmaceutical Group of the European Union. (2023). Retrieved from https://www.pgeu.eu/

Pharmaceutical Society of Australia. (2022). National naloxone program.

Pharmaceutical Society of Australia. (2022a). Rural pharmacy support programs.

Pharmaceutical Society of Australia. (2022b). Harm reduction and the role of pharmacists.

Pharmaceutical Society of Australia. (2023). Injectable buprenorphine: The role of pharmacists.

Pharmaceutical Society of Ireland. (2023). Retrieved from https://www.thepsi.ie/

Pharmacy Practice News. (2019). Pharmacist recovery programs: A lifeline for the profession.

Pijl, M., Bourque, J., Martens, M., & Cherniwchan, A. (2021). [No title provided]

Pottie, K., Ratnasingham, A., Medu, O., Welch, V., Dahal, G. P., Aubry, T., Magwood, O., Hannigan, T., Shoemaker, E. S., Rose, T., Saad, A., Crago, A. L., Poole, N., Tyndall, M., Lacroix, E., Dumont, D., Charlebois, A., Arya, N., Bhatt, M., ... Hwang, S. W. (2019). PEER umbre

Prawo farmaceutyczne. (2001). Pharmaceutical Law. Journal of Laws 2001 No. 126 item 1381.

Priester, M. A., Browne, T., Iachini, A., Clone, S., DeHart, D., & Seay, K. D. (2008). [No title provided]

Priester, M. A., Browne, T., Iachini, A., Clone, S., DeHart, D., & Seay, K. D. (2016). Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: An integrative literature review. Journal of Substance Abuse Treatment, 61, 47-59.

Public Health Scotland. (2023). Needle exchange surveillance initiative.

Pullen, E., & Oser, C. (2014). Barriers to substance abuse treatment in rural and urban communities: Counselor perspectives. Substance Use & Misuse, 49(7), 891-901.

Qato, D. M., Zenk, S., Wilder, J., Harrington, R., Gaskin, D., & Alexander, G. C. (2024). The availability of pharmacies in the United States: 2007-2015. PLOS ONE, 19(1), e0290683.

Radley, A., de Bruin, M., Inglis, S. K., Donnan, P. T., Hapca, A., Barclay, S. T., Fraser, A., & Dillon, J. F. (2021). Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: A pragmatic cluster randomised trial. The Lancet Gastroenterology & Hepatology, 6(9), 747-757.

Ramon, S., Moskalewicz, J., & Kirschbaum, K. M. (2017). The rights of people with mental health problems and the role of professionals: A European perspective. International Journal of Mental Health, 46(1), 54-62.

Regulation of the Minister of Health on basic conditions for running a pharmacy. (2002). Journal of Laws 2002 No. 121 item 1037.

Rural Health Information Hub. (2024). Rural prevention and treatment of substance use disorders toolkit.

Sajatovic, M., Velligan, D. I., Weiden, P. J., Valenstein, M. A., & Ogedegbe, G. (2009). [No title provided]

Saloner, B., Landis, R., Stein, B. D., & Barry, C. L. (2023). The Affordable Care Act in the heart of the opioid crisis: Evidence from West Virginia. Health Affairs, 42(1), 53-61.

Saloner, B., McGinty, E. E., Beletsky, L., Bluthenthal, R., Beyrer, C., Botticelli, M., & Sherman, S. G. (2021). [No title provided]

SAMHSA. (n.d.a). Screening, Brief Intervention, and Referral to Treatment (SBIRT). Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/

Samochowiec, J., Bieńkowski, P., & Wojnar, M. (2021). Mental health and substance use during COVID-19: An investigation of the pandemic's impact in Poland. Psychiatria Polska, 55(1), 7-19.

Savic, M., Best, D., Manning, V., & Lubman, D. I. (2017). Strategies to facilitate integrated care for people with alcohol and other drug problems: A systematic review. Substance Abuse Treatment, Prevention, and Policy, 12(1), 19.

Schindel, T. J., Yuksel, N., Breault, R., Daniels, J., Varnhagen, S., & Hughes, C. A. (2021). Pharmacists' learning needs in the era of expanding scopes of practice: Evolving practices and changing needs. Research in Social and Administrative Pharmacy, 17(1), 1714-1725.

Scottish Government. (2021). Medication assisted treatment (MAT) standards: Access, choice, support.

Scottish Government. (2023). [No title provided]

Sederer, L. I., Dewan, M. J., & Gupta, S. (2017). Addressing the opioid epidemic: The role of psychiatrists. Psychiatric Services, 68(6), 537-538.

Społeczna Inicjatywa Narkopolityki. (2022). Retrieved from https://sin.org.pl/

Strang, J., Groshkova, T., & Metrebian, N. (2020). New heroin-assisted treatment: Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. European Monitoring Centre for Drugs and Drug Addiction.

Strike, C., Watson, T. M., Kolla, G., Penn, R., & Bayoumi, A. M. (2020). [No title provided]

Subramony, A., & Hayfron, K. (2021). [No title provided]

Substance Abuse and Mental Health Services Administration (SAMHSA). (2017). [No title provided]

Substance Abuse and Mental Health Services Administration (SAMHSA). (2022a). [No title provided]

Substance Abuse and Mental Health Services Administration (SAMHSA). (2022c). [No title provided]

Substance Abuse and Mental Health Services Administration (SAMHSA). (2023a). [No title provided]

Substance Abuse and Mental Health Services Administration (SAMHSA). (2023b). [No title provided]

Substance Abuse and Mental Health Services Administration (SAMHSA). (2024a). [No title provided]

Substance Abuse and Mental Health Services Administration. (2017). Confidentiality of substance use disorder patient records. Federal Register, 82(11), 6052-6127.

Substance Abuse and Mental Health Services Administration. (2021). Facing addiction in America: The Surgeon General's report on alcohol, drugs, and health. SAMHSA.

Substance Abuse and Mental Health Services Administration. (2022). Telehealth for the treatment of serious mental illness and substance use disorders. SAMHSA.

Substance Abuse and Mental Health Services Administration. (n.d.-a). FindTreatment.gov. SAMHSA.

Świtalska, A., & Brola, W. (2020). Pharmaceutical care in Poland - Current state and development prospects. Farmacja Polska, 76(5), 267-272.

Taxman, F. S., & Belenko, S. (2012). [No title provided]

The Act on Counteracting Drug Addiction. (2005). Journal of Laws 2005 No. 179 item 1485.

The Kennedy Forum. (2021). [No title provided]

Townsend, T., Blo

Transform Drug Policy Foundation. (2021). [No title provided]

U.S. Government Accountability Office (GAO). (2023). [No title provided]

Uchtenhagen, A. (2010). [No title provided]

United Nations Office on Drugs and Crime (UNODC). (2023). [No title provided]

White, W. L., & Mojer-Torres, L. (2010). [No title provided]

WHO. (2019). Global status report on alcohol and health 2018.

WHO. (2020). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence.

Wojnar, M., & Klimkiewicz, A. (2019). Substance use disorders in Poland: Prevalence, harms, and treatment challenges. Psychiatria Polska, 53(3), 567-584.

World Health Organization (WHO). (2017). [No title provided]

World Health Organization (WHO). (2021). Retrieved from https://www.who.int/

World Health Organization (WHO). (2023). Harm reduction. Retrieved from https://www.who.int/

Test list:

• Test bullet item 1
• Test bullet item 2

Test numbered list:

1. Numbered item 1
2. Numbered item 2